

Electronic Supplementary Information (ESI)

Bismuth(III)-catalyzed bis-cyclization of propargylic diol-esters: a unified approach for the synthesis of [5,5]- and [6,5]-oxaspirolactones

Digambar A. Kambale^{†,§} Balasaheb R. Borade^{†,§} and Ravindar Kontham^{*,†,§}

[†]Organic Chemistry Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune-411008 (India).

[§]Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.

*E-mail: k.ravindar@ncl.res.in; konthamravindar@gmail.com

Table of Contents

S. No.	Contents	Page No.
1	General information	S2
2	Figure S1. Representative natural products possessing [5,5]- and [6,5]-oxaspirolactone skeleton	S3
3	Table S1. Reaction optimization	S3
4	Synthesis of alkynols and α -ketoesters	S4
5	Synthesis of propargylic diol esters and General procedures A-E	S5
6	Synthesis of [5,5]-unsaturated oxaspirolactones from propargylic diol esters	S33
7	Synthesis of [6,5]-unsaturated oxaspirolactones from propargylic diol esters	S45
8	¹ H, ¹³ C and 2D-NMR spectra	S51

1. General information:

All reactions were performed under argon atmosphere with oven (80 °C) or flame-dried glassware with septum seal. Tetrahydrofuran (THF) was distilled from sodium-benzophenone under argon atmosphere immediately prior to use. Dichloromethane and ethanol were freshly distilled over calcium hydride under argon atmosphere; 27 °C corresponds to the room temperature (rt) of the laboratory when the experiments were carried out. Reaction temperatures are reported as the temperature of the bath surrounding the reaction vessel. Analytical thin layer chromatography (TLC) was performed on TLC Silica gel 60 F254. Visualization was accomplished with short wave UV light, anisaldehyde or KMnO_4 staining solutions followed by heating. Chromatography was performed on silica gel (100-200 mesh) by standard techniques eluting with solvents as indicated. ^1H and ^{13}C NMR spectra were recorded on Bruker AV 200, 400 and 500 MHz spectrometers in solvents as indicated. Chemical shifts (δ) are given in ppm. The residual solvent signals were used as references and the chemical shifts converted to the TMS scale (CDCl_3 : $\delta \text{H} = 7.27$ ppm, $\delta \text{C} = 77.00$ ppm), the following abbreviations were used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; AB q, AB quartet; dd, doublet of doublet; td, triplet doublet; and br. broad. HRMS data were recorded on Q Exactive HybridTM Quadrupole-OrbitrapTM mass spectrometer (Thermo Scientific,TM Accela 1250 pump).

Experimental procedures for all new compounds and known compounds without published experimental procedures are described below. Compounds that are not presented in the main text (manuscript) are numbered starting from **S1**.

2. Figure S1.




Figure S1. Representative natural products possessing [5,5]- and [6,5]-oxaspirolactone skeleton

3. Table S1.

Table S1. Reaction optimization^a


entry	catalyst	solvent	yield (%) ^b
1	Bi(OTf) ₃	CH ₂ Cl ₂	85
2	AgOTf	CH ₂ Cl ₂	82
3	PPh ₃ AuCl+AgOTf	CH ₂ Cl ₂	84
4	AgOTf	THF	16
5	AuCl	CH ₂ Cl ₂	36
6	FeCl ₃	CH ₂ Cl ₂	12
7 ^c	FeCl ₃	CH ₃ CN	-
8	Cu(OTf) ₂	CH ₂ Cl ₂	18
9	In(OTf) ₃	CH ₂ Cl ₂	55
10	In(OTf) ₃	CH ₃ CN	51
11 ^c	Sc(OTf) ₃	CH ₂ Cl ₂	-
12	HgCl ₂	CH ₃ CN	34
13	Hg(OTf) ₂	CH ₃ CN	36
14	Hg(OTf) ₂	CH ₃ CN:H ₂ O	16
15 ^c	Pd(PPh ₃)Cl ₂	THF	-
16 ^c	<i>p</i> -TSA	CH ₂ Cl ₂	-
17	<i>p</i> -TSA, reflux	DCE	36
18	TfOH	CH ₂ Cl ₂	16
19 ^c	Bi(OTf) ₃ , MS-4 Å	CH ₂ Cl ₂	-
20 ^c	No catalyst	CH ₂ Cl ₂	-

^aReaction condition unless otherwise specified: **1a** (0.25 mmol), catalyst (10 mol %) in the indicated solvent (anhydrous, 2 mL) at rt (28 °C). ^bIsolated yield of **2a**. MS = Molecular Sieves. ^cNo conversion was observed.


4. Synthesis of alkynols and α -ketoesters

All the alkynols and α -ketoesters were synthesised by using known literature reports (entries A-C, Figure S1).^{1,2,3,4,5,6,7,8,9,10}

A. List of 4-pentyn-ols obtained using known procedures



B. List of 5-hexyn-ols obtained using known procedures



C. List of α -ketoesters obtained using known procedures




Figure S1. Structural details of building blocks **S1-S20**.

¹**S4, S7, S11 and S12** were purchased from commercial sources.

²Kambale, D. A.; Thorat, S. S.; Pratapure, M. S.; Gonnade, R. G.; Kontham, R. *Chem. Commun.* **2017**, 53, 6641–6644

³Thorat S. S.; Kataria P.; Kontham, R. *Org. Lett.* **2018**, 20, 3, 872–875

⁴Magnus, P.; Principe, L. M.; Slater, M. J. *J. Org. Chem.* **1987**, 52, 8, 1483–1486

⁵Ojima, D.; Yasui, A.; Tohyama, K.; Tokuzumi, K.; Torihara, E.; Ito, K.; Iwasaki, A.; Tomura, T.; Ojika, M.; Suenaga, K. *J. Org. Chem.* **2016**, 81, 20, 9886–9894

⁶Kamijo, S.; Dudley, G. B. *Tetrahedron Lett.*, **2006**, 47, 32, 5629–5632

⁷Sinha, D.; Biswas, A.; Singh, V. K. *Org. Lett.* **2015**, 17, 3302–3305


⁸Jeffries, A. T.; Moore, K. C.; Ondeyka, D. M.; Springsteen, A. W.; MacDowell, D. H. W. *J. Org. Chem.* **1981**, 46, 14, 2885–2889

⁹Hayashi, M.; Nakamura, S. *Angew. Chem. Int. Ed.* **2011**, 50, 2249–2252

¹⁰Yang, L.; Liu, Z.; Li, Y.; Lei, N.; Shen, Y.; Zheng, K. *Org. Lett.* **2019**, 21, 7702–7707.


5. Synthesis of propargylic diol esters and General procedures A-E

General procedure A for the synthesis of propargylic diol esters (**1** or **3**):



Propargylic diol esters were obtained by using known literature procedure.¹¹ A solution of alkynol (1.31 mmol) and α -ketoester (3.94 mmol) in 3.0 mL of THF was added to a mixture of Rh(acac)(CO)_2 (0.01g, 0.04 mmol, 3 mol%) and JohnPhos (0.035g, 0.12 mmol, 9.0 mol%) under argon atmosphere at room temperature, then the reaction mixture was warmed to 40 °C. After 24h at 40 °C, the mixture was allowed to cool to room temperature, diluted and extracted with CH_2Cl_2 , concentrated under reduced pressure and purified by silica gel column chromatography (using ethyl acetate/petroleum ether) to afford propargylic diol ester (**1** or **3**).

General procedure B for the synthesis of THP- protected propargylic diol esters (**5**):




To a solution alkynol (16.9 mmol) in an anhydrous THF (30 mL) under argon atmosphere was added $n\text{-BuLi}$ solution (1.6 M in hexane, 25.35 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of α -ketoester (2.2 mL, 18.6 mmol) in an anhydrous THF (10 mL) was added at the same temperature and stirred the reaction mixture for 30 min. Then the reaction mixture was allowed to warm tort and stirred until completion of reaction monitored by TLC. Reaction was quenched through the slow addition of saturated aqueous NH_4Cl solution at 0 °C, extracted with ethyl acetate, dried over an anhydrous Na_2SO_4 , filtered, and concentrated

¹¹Dhondi, P. D.; Carberry, P.; Choi, L. B.; Chisholm, J. D. *J. Org. Chem.*, **2005**, 72(25), 9590-9596


under vacuum. Purification by column chromatography (SiO₂, EtOAc/hexane) afforded THP-protected propargylic diol ester (5).

General procedure C for the synthesis of TBS-protected propargylic diol ester (5):



To a solution of *tert*-butyldimethyl silyl protected alkynol (1.87 mmol) in an anhydrous THF (10 mL) under argon was added *n*-BuLi (1.6 M in hexane, 2.81 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of α -ketoester in an anhydrous THF was added at the same temperature and stirred it for 30 min. Then the reaction mixture was allowed to warm to rt and stirred till the complete conversion of starting material monitored by TLC. Reaction was quenched with saturated aqueous NH₄Cl solution at 0 °C, warmed to rt, extracted with ethyl acetate, dried over anhydrous Na₂SO₄, filtered and concentrated under vacuum. Purification by flash column chromatography (SiO₂, EtOAc/hexane) afforded TBS-protected propargylic diol ester (5).


General procedure D for the synthesis of propargylic diol ester (1 or 3) from THP-protected propargylic diol ester (5):



To a solution of THP-protected propargylic diol ester (8.5mmol) in ethanol was added *p*-toluenesulfonic acid (0.85 mmol) at 0°C and then it was slowly warmed to rt. The resulting reaction mixture was stirred at rt till the complete conversion of starting material. Then the ethanol was evaporated under reduced pressure, diluted with ethyl acetate and quenched with saturated aqueous NaHCO₃ solution and extracted with ethyl acetate (3x25 mL). Combined


organic layers were dried over an anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to afford the crude product, which was purified by silica gel column chromatography (SiO_2 , EtOAc/hexanes) to afford propargylic diol ester (**1** or **3**).

General procedure E for the synthesis of propargylic diol ester from TBS-protected propargylic diol ester (**5**):



TBS-protected propargylic diol ester (**5**) (0.85 mmol) was placed in a flame-dried, two-neck, round-bottom flask under argon. To this was added an anhydrous THF (10 mL), and the mixture was cooled to 0 °C. TBAF (1.0 M in THF, 0.94 mmol) was then added slowly at 0 °C. The cooling bath was removed, and the system was allowed to stir at rt for 2h. After complete conversion of starting material, the reaction mixture was concentrated under reduced pressure and subjected for column chromatography (SiO_2 , EtOAc/hexanes) to afford the propargylic diol ester (**1** or **3**).

Synthesis of **1a**:




Ethyl 2-hydroxy-2-methyl-5-(1-(((tetrahydro-2H-pyran-2-yl) oxy) methyl) cyclohexyl) pent-3-ynoate (S22): Following *General Procedure B*, a solution of ((1-(prop-2-yn-1-yl) cyclohexyl)methoxy) tetrahydro-2H-pyran² (**S21**) (4g, 16.9 mmol) in anhydrous THF (30 mL) under argon was treated with *n*-BuLi (1.6 M in hexane, 26.5 mL, 42.35 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl pyruvate (**S11**) (2.2 mL, 18.6

mmol) in an anhydrous THF (10 mL) was added to give ethyl 2-hydroxy-2-methyl-5-(1-(((tetrahydro-2*H*-pyran-2-yl)oxy)methyl)cyclohexyl)pent-3-ynoate (**S22**) (3.0 g, 68%) as yellow oil. TLC: R_f = 0.3 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 4.63-4.51 (m, 1H), 4.38-4.14 (m, 2H), 3.93-3.78 (m, 1H), 3.71-3.57 (m, 1H), 3.56-3.4 (m, 2H), 3.27-3.11 (m, 1H), 2.29 (s, 2H), 1.84-1.73 (m, 2H), 1.7-1.64 (m, 4H), 1.6-1.51 (m, 4H), 1.45-1.4 (m, 9H), 1.32 (t, J = 6.87 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 173.2, 98.8, 82.9, 81.7, 72.1, 67.9, 62.6, 61.6, 37.3, 32.3, 32.2, 30.5, 27.3, 26.1, 25.8, 25.5, 21.6, 19.2, 14.0; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₂₀H₃₂O₅Na 375.2142; found 375.2135.

Ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclohexyl)-2-methylpent-3-ynoate (1a): Following *General Procedure C*, to a solution of ethyl 2-hydroxy-2-methyl-5-(1-(((tetrahydro-2*H*-pyran-2-yl)oxy)methyl)cyclohexyl)pent-3-ynoate (**S22**) (3 g, 8.5 mmol) in ethanol was added *p*-toluenesulfonic acid (0.16g, 0.85 mmol) to afford ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclohexyl)-2-methylpent-3-ynoate (**1a**) (1.25 g, 66%) as a colourless liquid. TLC: R_f = 0.4 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 4.36-4.15 (m, 2H), 3.95 (s, 1H), 3.47 (s, 2H), 2.40 (br. s, 1H), 2.24 (s, 2H), 1.63 (s, 3H), 1.47-1.25 (m, 13H); ¹³C NMR (CDCl₃, 126 MHz) δ 173.0, 82.6, 81.9, 68.2, 68.0, 62.6, 37.9, 31.9, 27.4, 26.1, 25.2, 21.5, 14.0; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₅H₂₄O₄Na 291.1567; found 291.1563.


Synthesis of 1b:



Ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclohexyl)-2-phenylpent-3-ynoate (1b): Following *General Procedure A*, a solution of (1-(prop-2-yn-1-yl)cyclohexyl)methanol (**S1**) (0.2 g, 1.31 mmol) and ethyl phenyl glyoxylate (**S12**) (0.7 g, 3.94 mmol) in 3 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.01 g, 0.04 mmol, 3 mol%) and JohnPhos (0.035 g, 0.12 mmol, 9 mol%) to afford ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclohexyl)-2-phenylpent-3-ynoate (**1b**) (0.107 g, 62%) as colourless liquid. TLC: R_f = 0.4 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.73-7.59 (m, 2H), 7.42-7.27 (m, 3H), 4.35-4.08 (m, 3H), 3.57 (s, 2H), 2.39 (s, 2H), 1.51-1.38 (m, 10H), 1.27-1.18 (m, 3H); ¹³C NMR (CDCl₃, 101 MHz) δ 172.2,


139.8, 128.6, 128.3, 126.1, 84.9, 80.7, 72.9, 68.7, 63.4, 38.2, 32.0, 31.9, 26.1, 25.6, 25.4, 21.5, 13.9; HRMS (ESI) m/z : $[M+Na]^+$ calcd for $C_{20}H_{26}O_4Na$ 353.1721; found 353.1723.

Synthesis of 1c:



Ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclohexyl)-2-(4-methoxyphenyl) pent-3-ynoate (1c): Following *General Procedure A*, to a solution of (1-(prop-2-yn-1-yl)cyclohexyl)methanol (**S1**) (0.2 g, 1.13 mmol) and ethyl anisylglyoxylate (**S13**) (0.82 g, 3.94 mmol) in 3 mL of THF was added $Rh(acac)(CO)_2$ (0.1 g, 0.039 mmol, 3 mol%) and JohnPhos (0.035g, 0.118mmol, 9 mol%) to afford ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclohexyl)-2-(4-methoxyphenyl) pent-3-ynoate (**1c**) (0.128 g, 27% (54% brsm) as a colourless liquid. TLC: R_f = 0.2 (SiO₂, 30% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.66-7.50 (m, 2H), 6.96-6.81 (m, 2H), 4.38-4.08 (m, 3H), 3.81 (s, 3H), 3.56 (s, 2H), 2.38 (s, 2H), 1.56-1.36 (m, 10H), 1.26-1.2 (m, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 172.3, 159.7, 131.9, 127.4, 113.6, 84.7, 80.8, 72.5, 68.6, 63.3, 55.3, 38.2, 32.0, 26.1, 25.5, 21.5, 13.8; HRMS (ESI) m/z : $[M+Na]^+$ calcd for $C_{21}H_{28}O_5Na$ 383.1829; found 383.1829.


Synthesis of 1d:



Ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclohexyl)-2-(p-tolyl)pent-3-ynoate (1d): Following *General Procedure A*, to a solution of (1-(prop-2-yn-1-yl)cyclohexyl)methanol (**S1**) (0.2 g, 1.32mmol) and ethyl *p*-tolylglyoxylate (**S14**) (0.76 g, 3.96 mmol) in 5 mL of THF was added to $Rh(acac)(CO)_2$ (0.01 g, 0.039 mmol, 3 mol%) and JohnPhos (0.035 g, 0.119 mmol, 9 mol%) to

afford ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclohexyl)-2-(*p*-tolyl)pent-3-ynoate (**1d**) (0.074 g, 16% (32% brsm) as a colourless liquid. TLC: R_f = 0.2 (SiO₂, 30% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.54 (d, J = 8.39 Hz, 2H), 7.16 (d, J = 8.39 Hz, 2H), 4.48 (br. s, 1H), 4.34-4.09 (m, 2H), 3.53 (s, 2H), 2.39-2.32 (m, 5H), 1.51-1.34 (m, 10H), 1.22 (t, J = 6.87 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 172.1, 138.2, 136.9, 128.9, 125.9, 84.8, 80.6, 72.8, 68.3, 63.12, 38.1, 31.9, 26.1, 25.3, 21.4, 21.0, 13.8; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₂₁H₂₈O₄Na 367.1880; found 367.1876.

Synthesis of **1e**:




Ethyl-5-(1-(((*tert*-butyldimethylsilyl)oxy)methyl)cyclohexyl)-2-hydroxy-2-(phenyl

ethynyl)pent-3-ynoate (**S24**): Following *General procedure C*, to a solution of *tert*-butyldimethyl((1-(prop-2-yn-1-yl)cyclohexyl)methoxy)silane¹² (**S23**) (0.5 g, 1.87 mmol) in an anhydrous THF (5 mL) under argon was added *n*-BuLi solution (1.6 M in hexane, 1.7 mL, 2.81 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl 2-oxo-4-phenylbut-3-ynoate (**S17**) (0.45 g, 2.2 mmol) in an anhydrous THF (5 mL) was added at the same temperature to give ethyl 5-(1-(((*tert*-butyldimethylsilyl) oxy) methyl) cyclohexyl)-2-hydroxy-2-(phenylethynyl)pent-3-ynoate (**S24**) (0.43 g, 49%) as a colourless liquid. TLC : R_f = 0.6 (SiO₂, 10% EtOAc /hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.72-7.62 (m, 1H), 7.5-7.44 (m, 2H), 7.35-7.31 (m, 2H), 4.44- 4.37 (m, 2H), 3.87 (br. s, 1H), 3.49-3.41 (m, 2H), 2.3 (s, 2H), 1.44-1.38 (m, 13H), 0.89 (s, 9H), 0.05 (s, 6H); ¹³C NMR (CDCl₃, 126 MHz): δ 169.2, 133.8, 132.0, 128.9, 128.8, 128.2, 121.7, 85.4, 84.2, 83.5, 78, 67.5, 63.9, 63.5, 63.3, 38.5, 31.8, 31.7, 26.2, 25.9, 21.6, 18.2, 14.0, -5.5; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₂₈H₄₀O₄NaSi 491.2588; found 491.2588.


¹²Aponick, A.; Li, C. Y.; Palmes, J. A. *Org. Lett.* **2009**, *11*(1), 121-124

Ethyl-2-hydroxy-5-(1-(hydroxymethyl)cyclohexyl)-2-(phenylethynyl)pent-3-ynoate (1e):

Following *General procedure E*, to a stirred solution of ethyl 5-(1-(((*tert*-butyldimethylsilyl)oxy)methyl)cyclohexyl)-2-hydroxy-2-(phenylethynyl)pent-3-ynoate (**S24**) (0.4 g, 0.85 mmol) in an anhydrous THF at 0 °C, solution of TBAF (1.0 M in THF, 1 mL, 0.94 mmol) was added to afford ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclohexyl)-2-(phenylethynyl)pent-3-ynoate (**1e**) (0.187 g, 62%) as colourless liquid. TLC: R_f = 0.40 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.5-7.45 (m, 2H), 7.37-7.29 (m, 3H), 4.46-4.33 (m, 2H), 3.98 (br. s, 1H), 3.56 (s, 2H), 2.34 (s, 2H), 1.49-1.37 (m, 13H); ¹³C NMR (CDCl₃, 101 MHz): δ 169, 132, 129.1, 128.9, 128.3, 127.9, 121.5, 85.2, 83.8, 83.7, 78.6, 68.5, 64.1, 63.5, 38.3, 32, 26.1, 21.6, 14; HRMS (ESI) m/z : [M+H]⁺ calcd for C₂₂H₂₇O₄ 355.1904; found 355.1893.


Synthesis of 1f:

Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-methylpent-3-ynoate (1f): Following *General procedure A*, to a solution of (1-(prop-2-yn-1-yl)cyclopentyl)methanol (**S2**) (0.2 g, 1.5 mmol) and ethyl pyruvate (**S11**) (0.17 g, 1.5 mmol) in 2 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.011 g, 0.043 mmol) and JohnPhos (0.0038 g, 0.13 mmol) under argon to afford ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-methylpent-3-ynoate (**1f**) (0.25 g, 68%) as a colourless liquid. TLC: R_f = 0.39 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 4.29 (q, J = 6.7 Hz, 2H), 3.53 (s, 1H), 3.48 (s, 2H), 2.3 (s, 2H), 1.82 (br. s, 1H), 1.66 (s, 3H), 1.65-1.55 (m, 4H), 1.54-1.42 (m, 4H), 1.33 (t, J = 6.7 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 173.1, 83.4, 80.9, 68.9, 67.9, 62.8, 47.3, 34.1, 27.4, 26.9, 25.2, 14; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₄H₂₃O₄ 255.1591, found 255.1586.


Synthesis of **1g**:

Ethyl-5-(1-(((*tert*-butyldimethylsilyl)oxy)methyl)cyclopentyl)-2-hydroxy-2-phenylpent-3-ynoate (5a**):** Following *General procedure C*, to a solution of *tert*-butyldimethyl((1-(prop-2-yn-1-yl)cyclopentyl)methoxy)silane (**S25**) (0.3 g, 1.2 mmol) in anhydrous THF (5 mL) under argon was added *n*-BuLi solution (1.6 M in hexane 1.1 mL, 1.78 mmol), then resultant mixture was stirred at -78 °C for 45 min. Next, the solution of ethyl phenyl glyoxylate (**S12**) (0.25 g, 1.4 mmol) in anhydrous THF was added at the same temperature to afford ethyl 5-(1-(((*tert*-butyldimethylsilyl)oxy)methyl)cyclopentyl)-2-hydroxy-2-phenylpent-3-ynoate (**5a**) (0.276 g, 54%) as yellowish oil. TLC: R_f = 0.5 (SiO₂, 10% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.68 (d, J = 7.32 Hz, 2H), 7.41-7.3 (m, 3H), 4.32-4.13 (m, 3H), 3.44 (s, 2H), 2.4 (s, 2H), 1.68-1.48 (m, 8H), 1.22 (t, J = 7.32 Hz, 3H), 0.91 (s, 9H), 0.05 (s, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 172.3, 139.9, 128.4, 128.1, 126.3, 86.3, 78.9, 72.9, 68.3, 68.3, 47.6, 33.9, 33.9, 26.9, 25.9, 25.4, 18.2, 13.8, -5.5; HRMS (ESI) m/z : [M+H]⁺ calcd for C₂₅H₃₉O₄Si 431.2612; found 431.2609.

Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-phenylpent-3-ynoate (1g**):** Following *General procedure E*, to a solution of ethyl 5-(1-(((*tert*-butyldimethylsilyl)oxy)methyl)cyclopentyl)-2-hydroxy-2-phenylpent-3-ynoate (**5a**) (0.1 g, 0.23 mmol) was added anhydrous THF (1.0 mL) and the mixture was cooled to 0 °C. Then TBAF (1.0 M in THF 0.072 mL, 0.28 mmol) was added slowly at 0 °C to obtain the ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-phenylpent-3-ynoate (**1g**) (0.07 g, 96%) as a viscous liquid. TLC: R_f = 0.3 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.7-7.62 (m, 2H), 7.41-7.3 (m, 3H), 4.34-4.24 (m, 1H), 4.23-4.12 (m, 1H), 3.54 (s, 2H), 2.42 (s, 2H), 1.71-1.5 (m, 8H), 1.23 (t, J = 7.32 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 172.1, 139.7, 128.5, 128.2, 126.1, 85.7, 79.5, 72.9, 68.9, 63.4, 47.4, 34.2, 27.1, 25.2, 13.8; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₉H₂₅O₄ 317.1747; found 317.1764.

Synthesis of **1h**:

Ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclopentyl)-2-(4-nitrophenyl) pent-3-ynoate (1h**):** Following *General procedure A*, to a solution of (1-(prop-2-yn-1-yl)cyclopentyl)methanol (**S2**) (0.2 g, 1.45 mmol) and ethyl 2-(4-nitrophenyl)-2-oxoacetate (**S15**) (0.323 g 1.45 mmol) in 5 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.011 g, 0.04 mmol, and JohnPhos (0.038 g, 0.13 mmol, under argon to afford ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclopentyl)-2-(4-nitrophenyl) pent-3-ynoate (**1h**) as a yellowish liquid (0.075 g, 14 %). TLC: $R_f = 0.4$ (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 8.3-8.17 (m, 2H), 7.94-7.79 (m, 2H), 4.37-4.13 (m, 3H), 3.53 (s, 2H), 2.44 (s, 2H), 1.73-1.47 (m, 8H), 1.24 (t, $J = 7.2$ Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 170.8, 147.9, 146.5, 127.5, 123.4, 86.8, 78.8, 72.4, 68.6, 63.9, 47.4, 34.3, 26.9, 25.2, 13.8; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₉H₂₄O₆N 362.1598; found 362.1596.

Synthesis of **1i**:

Ethyl 5-(1-(((*tert*-butyldimethylsilyl) oxy) methyl) cyclopentyl)-2-oxopent-3-ynoate (S27):

To a solution of *tert*-butyldimethyl((1-(prop-2-yn-1-yl)cyclopentyl)methoxy)silane (**S25**) (0.9 g, 3.56 mmol) in an anhydrous THF (10 mL) under argon was added *n*-BuLi (1.6 M in hexane 3.3 mL, 5.35 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl 2-(methoxy(methyl)amino)-2-oxoacetate¹³ (**S26**) (1.4 g, 11.8 mmol) in anhydrous THF was added at the same temperature and stirred it for 30 min. The reaction mixture was warmed to rt and stirred till the completion of reaction monitored by TLC. Reaction was quenched with saturated aqueous NH₄Cl solution at 0 °C, warmed to rt and diluted with water. The reaction mixture was extracted with EtOAc, dried over anhydrous Na₂SO₄, filtered and concentrated under vacuum. Purification by column chromatography (SiO₂, 2% EtOAc/hexanes) afforded ethyl 5-(1-(((*tert*-butyldimethylsilyl) oxy) methyl) cyclopentyl)-2-oxopent-3-ynoate (**S27**) (0.2 g, 16%) as a yellowish oil. TLC: *R_f* = 0.5 (SiO₂, 10% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 4.36 (q, *J* = 6.87 Hz, 2H), 3.42 (s, 2H), 2.58 (s, 2H), 1.67-1.51 (m, 8H), 1.38 (t, *J* = 6.87 Hz, 3H), 0.89 (s, 9H), 0.04 (s, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 169.6, 159.2, 102.3, 80.4, 68.1, 63.0, 47.8, 34.1, 27.6, 25.8, 25.2, 18.2, 13.9, -5.5; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₉H₃₃O₄Si 353.2143; found 353.2144.


Ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclopentyl)-2-(1*H*-indol-3-yl) pent-3-ynoate (1i):

To a solution of ethyl 5-(1-(((*tert*-butyldimethylsilyl)oxy)methyl)cyclopentyl)-2-oxopent-3-ynoate (**S27**) (0.15 g, 0.42 mmol) in anhydrous diethyl ether (3 mL) was added indole (**S28**) (0.1 g, 0.85 mmol) and cinchonide (0.012 g, 0.043 mmol) and stirred it at rt for 67h. After complete conversion, the reaction mixture was concentrated and filtered by using a short-pad of silica-gel to afford the crude **S29** (0.04 g, 76% (crude)) as a viscous liquid. TLC: *R_f* = 0.3 (SiO₂, 20% EtOAc/hexane), which was forwarded for the next step without purification. To a THF (2 mL) solution of **S29** (0.03 g, 0.064 mmol) under argon was added TBAF (1.0 M in THF, 0.03 mL) 0 slowly at 0 °C. Then the cooling bath was removed, and the system was allowed to stir at rt for 2h. After complete conversion, the reaction mixture was as such concentrated and subjected column chromatography (SiO₂, 30% EtOAc/hexane) to afford the ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclopentyl)-2-(1*H*-indol-3-yl) pent-3-ynoate (**1i**) (0.012 g, 76%) as a viscous liquid. TLC: *R_f* = 0.3 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 8.22 (s, 1H), 7.75 (d, *J* = 8.1 Hz, 1H), 7.47-7.42 (m, 1H), 7.37-7.32 (m, 1H), 7.22-7.16 (m, 1H), 7.14-7.09 (m,

¹³Honda, K.; Ohkura, S.; Hayashi, Y.; Kawauchi, S.; Mikami, K. *Chemistry - An Asian Journal*, **2018**, 13 (19), 2842-2846


1H), 4.36-4.27 (m, 1H), 4.23-4.09 (m, 2H), 3.52 (s, 2H), 2.41(s, 2H), 1.70-1.58 (m, 4H), 1.55-1.51 (m, 3H), 1.29-1.23 (m, 2H), 1.21 (t, $J = 7.25$ Hz, 3H); ^{13}C NMR (CDCl_3 , 126 MHz): δ 172.3, 136.8, 124.4, 123.9, 122.4, 120.2, 115.9, 111.3, 84.3, 79.8, 69.1, 68.9, 63.3, 47.4, 34.3, 29.7, 27.1, 25.2, 13.9; HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_4$ 355.1778; found 355.1727.

Synthesis of 1j:



Ethyl 2,7-dihydroxy-2,6,6-trimethylhept-3-ynoate(1j): Following *General procedure A*, a solution of 2,2-dimethylpent-4-yn-1-ol(**S3**) (0.3 g, 2.67mmol) and ethyl pyruvate (**S11**) (0.93 g, 8.02 mmol) in 5 mL of THF was added to a mixture of $\text{Rh}(\text{acac})(\text{CO})_2$ (0.020 g, 0.08 mmol, 3 mol%) and JohnPhos (0.071 g, 0.24 mmol, 9 mol%) under argon to afford ethyl 2,7-dihydroxy-2,6,6-trimethylhept-3-ynoate (**1j**) (0.11g, 18% (30% brsm) as colourless oil. TLC: $R_f = 0.3$ (SiO_2 , 40% EtOAc/hexanes); ^1H NMR (CDCl_3 , 400 MHz): δ 4.38-4.14 (m, 3H), 3.39 (s, 2H), 2.16 (s, 2H), 1.65 (s, 3H), 1.32 (t, $J = 6.87$ Hz, 3H), 0.95 (s, 6H); ^{13}C NMR (CDCl_3 , 101MHz): δ 173.0, 82.7, 81.8, 70.7, 67.9, 62.7, 35.7, 28.4, 27.5, 23.7, 14.0; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{12}\text{H}_{20}\text{O}_4\text{Na}$ 251.1254; found 251.1249.


Synthesis of 1k:



Ethyl 2,7-dihydroxy-6,6-dimethyl-2-phenylhept-3-ynoate (1k): Following *General procedure A*, a solution of 2,2-dimethylpent-4-yn-1-ol(**S3**) (0.3 g, 2.67 mmol) and ethyl phenylglyoxylate(**S12**) (1.4 g, 8.02 mmol) in 5 mL of THF was added to a mixture of $\text{Rh}(\text{acac})(\text{CO})_2$ (0.02 g, 0.08 mmol, 3 mol%) and JohnPhos(0.071g, 0.24 mmol, 9 mol%) under argon to afford ethyl 2,7-dihydroxy-6,6-dimethyl-2-phenylhept-3-ynoate(**1k**)(0.106g, 9% (35%brsm) as a yellowish oil. TLC: $R_f = 0.4$ (SiO_2 , 40% EtOAc/hexanes); ^1H NMR (CDCl_3 , 500 MHz): δ 7.70-7.59 (m, 2H), 7.40-7.32 (m, 3H), 4.34-4.09 (m, 3H), 3.4 5(s, 2H), 2.30 (s, 2H),


1.23 (t, $J = 6.87$ Hz, 3H), 1.02 (s, 6H); ^{13}C NMR (CDCl_3 , 126 MHz): δ 172.1, 139.7, 128.5, 128.2, 126.1, 85.0, 80.4, 72.9, 70.8, 63.3, 36.0, 28.6, 23.8, 13.8; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{22}\text{O}_4\text{Na}$ 313.141; found 313.1404.

Synthesis of 1l:



Ethyl 2,7-dihydroxy-2-(4-methoxyphenyl)-6,6-dimethylhept-3-ynoate (1l): Following *General procedure A*, a solution of 2,2-dimethylpent-4-yn-1-ol (**S3**) (0.2 g, 1.78 mmol) and ethyl anisylglyoxylate (**S13**) (1.11 g, 5.34 mmol) in 5 mL of THF was added to a mixture of $\text{Rh}(\text{acac})(\text{CO})_2$ (0.014 g, 0.053 mmol, 3 mol%) and JohnPhos (0.048 g, 0.16 mmol, 9 mol%) under argon to obtain ethyl 2,7-dihydroxy-2-(4-methoxyphenyl)-6,6-dimethylhept-3-ynoate (**1l**) (0.079 g, 14% (34% brsm) as colourless oil. TLC: $R_f = 0.3$ (SiO_2 , 40% EtOAc/hexanes); ^1H NMR (CDCl_3 , 400 MHz): δ 7.62-7.5 (m, 2H), 6.9-6.8 (m, 2H), 4.3-4.1 (m, 3H), 3.79 (s, 3H), 3.42 (s, 2H), 2.27 (s, 2H), 1.3-1.15 (m, 3H), 0.99 (s, 6H); ^{13}C NMR (CDCl_3 , 126 MHz): δ 172.4, 159.8, 132.1, 127.5, 113.7, 85.0, 80.7, 72.7, 70.9, 63.3, 55.4, 38.9, 36.1, 28.7, 24.0, 14; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{18}\text{H}_{24}\text{O}_5\text{Na}$ 343.1516; found 343.1511.


Synthesis of 1m:



Ethyl 2,7-dihydroxy-6,6-dimethyl-2-(p-tolyl)hept-3-ynoate (1m): Following *General procedure A*, a solution of 2,2-dimethylpent-4-yn-1-ol (**S3**) (0.2 g, 0.018 mmol) and ethyl *p*-tolylglyoxylate (**S14**) (1.03g, 5.34 mmol) in 5 mL of THF was added to a mixture of $\text{Rh}(\text{acac})(\text{CO})_2$ (0.014 g, 0.053 mmol, 3 mol%) and JohnPhos (0.048 g, 0.16 mmol, 9 mol%) under argon to afford ethyl 2,7-dihydroxy-6,6-dimethyl-2-(p-tolyl)hept-3-ynoate (**1m**) (0.096g,


18% (37% brsm) as a viscous liquid. TLC: R_f = 0.4 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.60-7.49 (m, 2H), 7.22-7.12 (m, 2H), 4.37-4.10 (m, 3H), 3.46 (s, 2H), 2.36 (s, 3H), 2.30 (s, 2H), 1.24(t, J = 7.63 Hz, 3H), 1.02 (s, 6H); ¹³C NMR (CDCl₃, 126 MHz): δ 172.3, 138.4, 136.9, 129.0, 126.0, 84.8, 80.5, 72.8, 71.0, 63.4, 36.0, 29.8, 28.8, 23.9, 21.1, 13.9; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₈H₂₄O₄Na 327.1567; found 327.1562.

Synthesis of 1n:



Ethyl 2-(4-fluorophenyl)-2,7-dihydroxy-6,6-dimethylhept-3-ynoate (1n): Following *General procedure A*, a solution of 2,2-dimethylpent-4-yn-1-ol (**S3**) (0.3 g, 2.67 mmol) and ethyl 2-(4-fluorophenyl)-2-oxoacetate (**S16**) (1.57 g, 8.02 mmol) in 5 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.021g, 0.08 mmol, 3 mol%) and JohnPhos (0.072 g, 0.24 mmol, 9 mol%) under argon to obtain ethyl 2-(4-fluorophenyl)-2,7-dihydroxy-6,6-dimethylhept-3-ynoate (**1n**) (0.088 g, 11% (31% brsm) as yellowish oil. TLC: R_f = 0.3 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.71-7.6 (m, 2H), 7.11-7.99 (m, 2H), 4.34-4.13 (m, 3H), 3.45 (s, 2H), 2.30 (s, 2H), 1.23 (t, J = 6.87 Hz, 3H), 1.02 (s, 6H); ¹³C NMR (CDCl₃, 126 MHz): δ 172.0, 135.5, 128.1, 128.0, 115.2, 115.0, 85.2, 80.3, 72.3, 70.9, 70.7, 63.5, 36.1, 36.0, 29.7, 29.0, 28.6, 23.9, 13.9; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₇H₂₁O₄FNa 331.1316; found 331.1308.


Synthesis of 1o:



Ethyl 2,7-dihydroxy-2-methylhept-3-ynoate (1o): Following *General procedure A*, a solution of 4-pentyn-1-ol (**S4**) (0.2 g, 2.4 mmol) and ethyl pyruvate (**S11**) (0.17 g, 1.5 mmol) in 2 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.018 g, 0.07 mmol) and JohnPhos (0.063 g,


0.21 mmol) under argon to afford ethyl 2, 7-dihydroxy-2-methylhept-3-ynoate (**1o**) (0.29 g, 60%) as a viscous liquid. TLC: R_f = 0.4 (SiO₂, 40% EtOAc/ hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 4.3(q, J = 6.87 Hz, 2H), 3.74 (t, J = 6.1 Hz, 2H), 2.35 (t, J = 6.87 Hz, 2H), 1.8-1.73 (m, 2H), 1.66 (s, 3H), 1.34 (t, J = 6.87 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 173.3, 84.4, 80.7, 67.9, 62.8, 61.6, 30.9, 27.4, 15.3, 14.0; HRMS (ESI) m/z : $[M+Na]^+$ calcd for C₁₀H₁₆O₄Na 223.0941; found 223.0939.

Synthesis of 5f:



Ethyl 2-hydroxy-7-((4-methoxybenzyl)oxy)-2-methylhept-3-ynoate (5f): Following *General procedure C*, to a solution of 1-methoxy-4-((pent-4-yn-1-yloxy)methyl)benzene¹⁴ (**S30**) (0.5 g, 2.44 mmol) in anhydrous THF (20 mL) under argon was added *n*-BuLi solution (1.6 M in hexane, 2.29 mL, 3.67mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl pyruvate (**S11**) (0.34 g, 2.93 mmol) in anhydrous THF was added at the same temperature to afford ethyl 2-hydroxy-7-((4-methoxybenzyl)oxy)-2-methylhept-3-ynoate (**5f**) (0.4 g, 61%) as colourless oil. TLC: R_f = 0.5 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.25 (d, J = 9.13 Hz, 2H), 6.88 (d, J = 8.76 Hz, 2H), 4.43 (s, 2H), 4.28 (q, J = 7.13 Hz, 2H), 3.8 (s, 3H), 3.51(t, J = 6.13 Hz, 2H), 3.45 (br. s, 1H), 2.32 (t, J = 7.13 Hz, 2H), 1.83-1.73 (m, 2H), 1.64 (s, 3H), 1.32 (t, J = 7.13 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 173.1, 159.2, 130.5, 129.2, 113.8, 84.3, 80.1, 72.6, 68.4, 67.9, 62.7, 55.3, 28.5, 27.4, 15.6, 14; HRMS (ESI) m/z : $[M+Na]^+$ calcd for C₁₈H₂₄O₅Na 343.1516; found 343.1511.

Synthesis of 1p:




¹⁴Chandrasekhar, S.; Rao, C. L.; Seenaiah, M.; Naresh, P.; Jagadeesh, B.; Manjeera, D.; Sarkar, A.; Bhadra, M. P.J. *Org. Chem*, **2009**, 74 (1), 401-404.

Ethyl 2-hydroxy-2-phenyl-7-((tetrahydro-2H-pyran-2-yl)oxy)hept-3-ynoate (5e): Following *General procedure C*, to a solution of 2-(pent-4-yn-1-yloxy)tetrahydro-2H-pyran¹⁵ (**S31**) (2 g, 11.9 mmol) in anhydrous THF (20 mL) under argon was added *n*-BuLi solution (1.6 M in hexane, 11.13 mL, 17.8 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl phenyl glyoxylate (**S12**) (2.5 mL, 14.2 mmol) in anhydrous THF was added at the same temperature to afford ethyl 2-hydroxy-2-phenyl-7-((tetrahydro-2H-pyran-2-yl)oxy)hept-3-ynoate (**5e**) (1.86 g, 62%) as a colourless liquid. TLC: R_f = 0.5 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.5-7.4 (m, 2H), 7.36-7.26 (m, 3H), 4.58 (s, 1H), 4.38 (q, J = 6.71 Hz, 2H), 4.21 (br. s, 1H), 3.88-3.7 (m, 2H), 3.54-3.36 (m, 2H), 2.3 (t, J = 7.32 Hz, 2H), 1.71-1.49 (m, 8H), 1.36 (t, J = 7.32 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 168.9, 132, 129, 128.2, 121.6, 98.7, 85.5, 85.4, 83.6, 66.8, 63.9, 63.5, 62.2, 30.6, 28.8, 25.4, 24.9, 19.5, 18.6, 13.9; HRMS (ESI) m/z : $[M+H]^+$ calcd for C₂₀H₂₇O₅ 347.1853, found 347.1863.

Ethyl 2,7-dihydroxy-2-phenylhept-3-ynoate (1p): Following *General procedure D*, to a solution of ethyl 2-hydroxy-2-phenyl-7-((tetrahydro-2H-pyran-2-yl)oxy)hept-3-ynoate (**5e**) (1.8 g, 0.52 mmol) in ethanol was added *p*-toluenesulfonic acid (0.5 g, 0.26 mmol) at 0 °C and then it was slowly warmed to rt to afford ethyl 2,7-dihydroxy-2-phenylhept-3-ynoate (**1p**) (1.25 g, 92%) as a colourless liquid. TLC: R_f = 0.4 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.72-7.60 (m, 2H), 7.43-7.29 (m, 3H), 4.35-4.14 (m, 3H), 3.79 (t, J = 6.10 Hz, 2H), 2.46 (t, J = 6.87 Hz, 2H), 1.89-1.77 (m, 3H), 1.22 (t, J = 6.87 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 172.1, 139.6, 128.5, 128.2, 126.1, 86.5, 79.05, 72.8, 63.4, 61.6, 30.9, 15.5, 13.9; HRMS (ESI) m/z : $[M+Na]^+$ calcd for C₁₅H₁₈O₄Na 285.1097; found 285.1089.

Synthesis of 1q:




Ethyl 2,7-dihydroxy-2-(*p*-tolyl)hept-3-ynoate (1q): Following *General procedure A*, a solution of pent-4-yn-1-ol (**S4**) (0.2 g, 2.37 mmol) and ethyl *p*-tolylglyoxylate (**S14**) (1.37 g, 7.13 mmol)

¹⁵Marino, J. P.; Nguyen, H. N. *J. Org. Chem.* **2002**, 67 (18), 6291-6296.

in 5 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.018 g, 0.071 mmol, 3 mol%) and JohnPhos (0.064g, 0.21 mmol, 9 mol%) to afford ethyl 2,7-dihydroxy-2-(*p*-tolyl)hept-3-ynoate (**1q**) (0.072g, 11% (27% brsm) as colourless oil. TLC: *R_f* = 0.4 (40% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.69-7.55 (m, 2H), 7.10-7.95 (m, 2H), 4.38-4.02 (m, 3H), 3.73-3.58 (m, 2H), 2.64 (t, *J* = 6.87 Hz, 2H), 2.35 (s, 3H), 1.77-1.57 (m, 2H), 1.2 (t, *J* = 7.33 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): 172.4, 136.9, 129.1, 126.1, 86.4, 79.3, 76.8, 72.8, 63.5, 61.8, 31.1, 15.6, 13.9; HRMS (ESI) *m/z*: [M+Na]⁺ calcd for C₁₆H₂₀O₄Na 299.1254; found 299.1250.

Synthesis of **1r**:




Ethyl-7-((*tert*-butyldimethylsilyl)oxy)-2-hydroxy-2-(4-methoxyphenyl)oct-3-ynoate (**S33**):

Following *General procedure C*, to a solution of *tert*-butyl(hex-5-yn-2-yloxy)dimethylsilane¹⁶ (**S32**) (0.5 g, 2.3 mmol) in an anhydrous THF (10 mL) under argon was added *n*-BuLi solution (1.6 M in hexane, 2.2 mL, 3.53 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl anisylglyoxylate (**S13**) (0.58 g, 2.82 mmol) in anhydrous THF was added at the same temperature to afford ethyl 7-((*tert*-butyldimethylsilyl)oxy)-2-hydroxy-2-(4-methoxyphenyl)oct-3-ynoate (**S33**) (0.35 g, 59% brms). TLC: *R_f* = 0.3 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.57(d, *J* = 9.1 Hz, 2H), 6.88(d, *J* = 8.88 Hz, 2H), 4.31-4.12(m, 3H), 4.0-3.87(m, 1H), 3.81(s, 3H), 2.47-2.26 (m, 2H), 1.71-1.66 (m, 2H), 1.22-1.20 (m, 3H), 1.16 (d, *J* = 6 Hz, 3H), 0.89 (s, 9H), 0.06 (s, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 172.4, 159.7, 132.1, 127.5, 113.5, 87.1, 78.6, 72.5, 67.2, 66.9, 64.4, 63.2, 55.3, 38.1, 30.3, 25.9, 25.3, 23.7, 18.8, 18.1, 15.3, 13.8, 13.6, -4.3, -4.8; HRMS (ESI) *m/z*: [M+Na]⁺ calcd for C₂₃H₃₆O₅NaSi 443.222; found 443.2216.

¹⁶Mulzer, J.; Berger, M. *J. Org. Chem.* **2004**, 69(3), 891-898

Ethyl 2,7-dihydroxy-2-(4-methoxyphenyl)oct-3-ynoate (1r): Following *General procedure E*, to a solution of ethyl 7-((*tert*-butyldimethylsilyl)oxy)-2-hydroxy-2-(4-methoxyphenyl)oct-3-ynoate (**S33**) (0.3 g, 0.71 mmol) was added anhydrous THF (5 mL), and the mixture was cooled to 0 °C. TBAF (1.0 M in THF, 1 mL, 0.85 mmol) was then added to afford ethyl 2,7-dihydroxy-2-(4-methoxyphenyl)oct-3-ynoate (**1r**) (0.1 g, 57% brsm) as a viscous liquid, TLC: R_f = 0.4 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 200 MHz): δ 7.63-7.5 (m, 2H), 6.95-6.8 (m, 2H), 4.34-4.13 (m, 2H), 4.05-3.88 (m, 1H), 3.81 (s, 3H), 2.45 (t, J = 6.69 Hz, 2H), 1.82 (br. s, 1H), 1.78-1.64 (m, 2H), 1.3-1.2 (m, 6H); ¹³C NMR (CDCl₃, 56 MHz): δ 172.3, 159.8, 131.9, 127.5, 113.6, 86.6, 79.2, 72.5, 67.1, 63.3, 55.3, 37.3, 29.7, 23.4, 15.5, 13.8; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₇H₂₂O₅Na 329.1359; found 329.1354.

Synthesis of 1s:




Ethyl 7-((*tert*-butyldimethylsilyl)oxy)-2-(4-fluorophenyl)-2-hydroxyoct-3-ynoate (**S34**):

Following *General procedure C*, to a solution of *tert*-butyl(hex-5-yn-2-yl)oxydimethylsilane¹⁵ (**S32**) (0.5 g, 2.35 mmol) in anhydrous THF (10 mL) under argon was added *n*-BuLi solution (1.6 M in hexane, 2.2 mL, 3.53 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl 2-(4-fluorophenyl)-2-oxoacetate (**S16**) (0.58 g, 2.82 mmol) in anhydrous THF was added at the same temperature and again stirred it for 30 min to afford ethyl 7-((*tert*-butyldimethylsilyl)oxy)-2-(4-fluorophenyl)-2-hydroxyoct-3-ynoate (**S34**) (0.437 g, 74% brsm). TLC: R_f = 0.3 (SiO₂, 20% EtOAc /hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.71-7.57 (m, 2H), 7.10-6.97 (m, 2H), 4.28-4.10 (m, 3H), 3.95-3.87 (m, 1H), 2.41-2.34 (m, 2H), 1.68-1.65 (m, 1H), 1.58-1.54 (m, 1H), 1.16 (d, J = 6.10 Hz, 3H), 0.90-0.86 (m, 12H), 0.06 (s, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 172.1, 164.0, 161.6, 135.6, 128.2, 128.1, 115.1, 114.9, 87.3, 78.3, 72.3, 67.1, 38.0, 30.2, 25.8, 23.7, 18.7, 18.0, 15.3, 13.5, -4.28, -4.74; HRMS (ESI) m/z : [M+H]⁺ calcd for C₂₂H₃₄O₄FSi 409.2205; found 409.2203.


Ethyl 2-(4-fluorophenyl)-2,7-dihydroxyoct-3-ynoate (1s): Following *General procedure E*, to a solution ethyl 7-((*tert*-butyldimethylsilyl)oxy)-2-(4-fluorophenyl)-2-hydroxyoct-3-ynoate (**S34**) (0.4 g, 0.98 mmol) in anhydrous THF (5 mL) was added TBAF (1.0 M in THF, 1 mL, 1.07 mmol) at 0 °C to afford ethyl 2-(4-fluorophenyl)-2,7-dihydroxyoct-3-ynoate (**1s**) (0.131 g, 57% brsm). TLC: R_f = 0.4 (SiO₂, 40% EtOAc/ hexanes) as a viscous liquid; ¹H NMR (CDCl₃, 500 MHz): δ 7.69-7.57(m, 2H), 7.1-6.96 (m, 2H), 4.35-4.17 (m, 3H), 4.02-3.86 (m 1H), 2.5-2.37 (m, 2H), 1.77-1.64 (m, 2H), 1.27-1.15 (m, 6H); ¹³C NMR (CDCl₃, 126 MHz): δ 171.9, 164.1, 161.6, 161.3, 135.6, 128.2, 128.1, 115.2, 115.0, 86.9, 78.9, 72.4, 67.1, 63.5, 37.2, 23.4, 15.4, 13.8; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₆H₁₉O₄FNa 317.1160; found 317.1154.

Synthesis of 1t:




Ethyl 2-hydroxy-5-(2-hydroxycyclohexyl)-2-methylpent-3-ynoate (1t): Following *General procedure A*, a solution of 2-(prop-2-yn-1-yl)cyclohexan-1-ol (**S6**) (0.15 g, 1.1 mmol) and ethyl pyruvate (**S11**) (0.13 g, 1.1 mmol) in 0.5 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.0083 g, 0.0033 mmol) and JohnPhos (0.029 g, 0.1 mmol) under argon to afford ethyl 2-hydroxy-5-(2-hydroxycyclohexyl)-2-methylpent-3-ynoate (**1t**) (0.16 g, 57%) as a colourless liquid. TLC: R_f = 0.4 (50% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 4.34-4.24(m, 2H), 3.48 (br. s, 1H), 3.36-3.21 (m, 1H), 2.55-2.49 (m, 1H), 2.34-2.21 (m, 1H), 2.02-1.93 (m, 1H), 1.88-1.71 (m, 2H), 1.66 (s, 3H), 1.5-1.37 (m, 1H), 1.36-1.23 (m, 8H); ¹³C NMR (CDCl₃, 101 MHz): δ 173.1, 83.3, 81.4, 73.6, 68, 62.7, 44.1, 35.5, 30.4, 27.4, 25.4, 24.9, 22.06, 14.03; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₄H₂₂O₄Na 277.1410; found 277.1409.

Synthesis of 1u:




Ethyl 2-hydroxy-5-(2-hydroxycyclohexyl)-2-(4-nitrophenyl)pent-3-ynoate (1u**):** Following *General procedure A*, a solution of 2-(prop-2-yn-1-yl)cyclohexan-1-ol (**S6**) (0.15 g, 1.1 mmol) and ethyl 2-(4-nitrophenyl)-2-oxoacetate (**S15**) (0.242 g, 1.1 mmol) in 1 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.008 g, 0.032 mmol) and JohnPhos (0.028 mg, 0.1 mmol) under argon to afford ethyl 2-hydroxy-5-(2-hydroxycyclohexyl)-2-(4-nitrophenyl)pent-3-ynoate (**1u**) (0.25 g, 62%) as yellowish oil. TLC: R_f = 0.4 (40% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 8.22 (d, J = 8.77 Hz, 2H), 7.88 (d, J = 8.39 Hz, 2H), 4.49 (br. s, 1H), 4.35-4.25 (m, 1H), 4.23-4.13 (m, 1H), 3.41-3.28 (m, 1H), 2.62 (dd, J = 4.20, 16.78 Hz, 1H), 2.44 (dd, J = 7.25, 16.78 Hz, 1H), 2.0-1.88 (m, 2H), 1.77-1.67 (m, 2H), 1.55-1.43 (m, 1H), 1.29-1.18 (m, 8H); ¹³C NMR (CDCl₃, 126 MHz): δ 171.0, 148.0, 146.6, 127.6, 123.4, 86.8, 79.1, 73.6, 72.4, 63.9, 44.1, 35.7, 30.5, 25.4, 24.9, 22.2, 13.8; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₉H₂₃O₆NNa 384.1418; found 384.1440.

Synthesis of **3a**:




Ethyl 2, 8-dihydroxy-2-methyloct-3-ynoate (3a**):** Following *General procedure A*, a solution of hex-5-yn-1-ol (**S7**) (0.2 g, 2.04 mmol) and ethyl pyruvate (**S11**) (0.71 g, 6.1 mmol) in 3 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.016 g, 0.061 mmol, 3 mol%) and JohnPhos (0.055 g, 0.18 mmol, 9 mol%) under argon to afford ethyl 2,8-dihydroxy-2-methyloct-3-ynoate (**3a**) (0.119 g, 52%) as a colourless liquid. TLC: R_f = 0.2 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 4.29 (q, J = 6.87 Hz, 2H), 3.66 (t, J = 6.1 Hz, 2H), 2.25 (t, J = 6.87 Hz, 2H), 1.67-1.58 (m, 7H), 1.33 (t, J = 7.63 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 173.1, 84.5, 80.2, 67.9, 62.7, 62.2, 31.6, 27.3, 24.5, 18.4, 14.0; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₁H₁₈O₄Na 237.1097; found 237.1091.

Synthesis of 3b:**Ethyl 2-hydroxy-2-phenyl-8-((tetrahydro-2H-pyran-2-yl)oxy) oct-3-ynoate (S36):**

Following *General procedure B*, to a solution of 2-(hex-5-yn-1-yloxy)tetrahydro-2H-pyran¹⁶ (**S35**) (1.5 g, 8.23 mmol) in anhydrous THF (20 mL) under argon was added *n*-BuLi solution (1.6M in hexane, 6.18 mL, 9.9mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl phenyl glyoxylate (**S12**) (1.76 g, 9.9 mmol) in anhydrous THF was added at the same temperature and stirred it for 30 min to afford ethyl 2-hydroxy-2-phenyl-8-((tetrahydro-2H-pyran-2-yl)oxy)oct-3-ynoate (**S36**) (1.2 g, 40%) as a yellowish oil. TLC: R_f = 0.3 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.69 (d, J = 7.63 Hz, 2H), 7.4-7.26 (m, 3H), 4.6 (s, 1H), 4.37-4.25 (m, 2H), 4.35 (br. s, 1H), 3.82-3.76 (m, 2H), 3.55-3.39 (m, 2H), 2.3 (t, J = 6.87Hz, 2H), 1.89-1.49 (m, 10H), 1.22(t, J = 6.87 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 168.9, 132.0, 129.0, 128.2, 121.6, 98.7, 85.5, 83.6, 66.8, 63.8, 63.5, 62.2, 30.6, 28.8, 25.4, 24.9, 19.5, 18.6, 13.9; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₂₁H₂₈O₅Na 383.1829; found 383.1823.

Ethyl 2,8-dihydroxy-2-phenyloct-3-ynoate (3b): Following *General procedure D*, to a solution of ethyl 2-hydroxy-2-phenyl-8-((tetrahydro-2H-pyran-2-yl)oxy)oct-3-ynoate (**S36**) (1.1 g, 3.05 mmol) in ethanol was added *p*-toluenesulfonic acid (0.052g, 0.305mmol) at 0 °C and then it was slowly warmed to rt to afford ethyl 2,8-dihydroxy-2-phenyloct-3-ynoate (**3b**) (0.58 g, 68%) as a colourless liquid. TLC: R_f = 0.4 (SiO₂, 40%EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.72-7.62 (m, 2H), 7.40-7.28 (m, 3H), 4.35 (br. s, 1H), 4.25-4.05 (m, 2H), 3.67 (t, J = 6.13 Hz, 2H), 2.36 (t, J = 6.88 Hz, 2H), 1.90 (br. s, 1H), 1.71-1.66 (m, 2H), 1.6-1.5 (m, 2H), 1.29-1.17 (m, 2H), 0.84 (t, J = 7.25 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 172.2, 139.7, 128.4, 128.1, 126.1, 86.9, 78.8, 72.8, 67.0, 62.2, 31.7, 30.2, 24.6, 18.7, 18.5, 13.4; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₆H₂₀O₄Na 299.1254; found 299.1250.


Synthesis of 5d and 3c:



Ethyl 2-hydroxy-2-(4-methoxyphenyl)-8-((tetrahydro-2H-pyran-2-yl)oxy)oct-3-ynoate (5d): Following *General procedure B*, to a solution of 2-(hex-5-yn-1-yloxy)tetrahydro-2H-pyran (**S35**) (0.5 g, 2.74 mmol) in anhydrous THF (20 mL) under argon was added *n*-BuLi solution (1.6 M in hexane, 2.5 mL, 4.11 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl anisylglyoxylate (**S13**) (0.68 g, 3.29 mmol) in anhydrous THF was added at the same temperature and stirred it for 30 min to afford ethyl 2-hydroxy-2-(4-methoxyphenyl)-8-((tetrahydro-2H-pyran-2-yl)oxy)oct-3-ynoate (**5d**) (0.412 g, 52%) as a yellowish oil. TLC: R_f = 0.5 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.58 (d, J = 8.77 Hz, 2H), 6.88 (d, J = 8.77 Hz, 2H), 4.62-4.54 (m, 1H), 4.33-4.24 (m, 1H), 4.22-4.12 (m, 2H), 3.89-3.75 (m, 5H), 3.53-3.40 (m, 2H), 2.37 (d, J = 6.87 Hz, 2H), 1.88-1.80 (m, 1H), 1.76-1.66 (m, 5H), 1.60-1.50 (m, 4H), 1.22 (t, J = 6.87 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 172.4, 159.7, 132.1, 127.5, 113.5, 98.8, 87, 79, 72.5, 66.9, 63.2, 62.3, 55.3, 30.7, 28.9, 25.5, 25.2, 19.6, 18.7, 13.9; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₂₂H₃₀O₆Na 413.1935; found 413.1927.


Ethyl 2,8-dihydroxy-2-(4-methoxyphenyl)oct-3-ynoate (3c): Following *General procedure D*, to a solution of ethyl 2-hydroxy-2-(4-methoxyphenyl)-8-((tetrahydro-2H-pyran-2-yl)oxy)oct-3-ynoate (**5d**) (0.15 g, 0.384 mmol) in ethanol was added *p*-toluenesulfonic acid (0.007 g, 0.038 mmol) at 0 °C and then it was slowly warmed to rt to afford ethyl 2,8-dihydroxy-2-(4-methoxyphenyl)oct-3-ynoate (**3c**) (0.087 g, 74%) as a colourless liquid. TLC: R_f = 0.4 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.62-7.5 (m, 2H), 6.94-6.82 (m, 2H), 4.13-4.11 (m, 3H), 3.8 (s, 3H), 3.67 (t, J = 6.13 Hz, 2H), 2.36 (t, J = 6.88 Hz, 2H), 1.78-1.6 (m, 4H), 1.21 (t, J = 7.13 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 172.3, 159.7, 132.03, 127.5, 113.6, 86.9, 79.05, 72.6, 63.2, 62.2, 55.3, 31.7, 24.6, 18.6, 13.8; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₇H₂₂O₅Na 329.1359; found 329.1354.

Synthesis of 3d:




Ethyl 2-hydroxy-8-((tetrahydro-2H-pyran-2-yl)oxy)-2-(p-tolyl)oct-3-ynoate (S37): Following *General procedure B*, to a solution of 2-(hex-5-yn-1-yloxy)tetrahydro-2H-pyran (**S35**) (0.3 g, 1.64 mmol) in anhydrous THF (20 mL) under argon was added *n*-BuLi solution (1.6 M in hexane, 1.54 mL, 2.46 mmol). The resultant mixture was stirred at -78°C for 45 min. Then the solution of ethyl *p*-tolylglyoxylate (**S14**) (0.37 g, 1.57 mmol) in anhydrous THF was added at the same temperature and stirred it for 30 min to afford ethyl 2-hydroxy-8-((tetrahydro-2H-pyran-2-yl)oxy)-2-(p-tolyl)oct-3-ynoate (**S37**) (0.338 g, 55%) as a yellowish oil. TLC: $R_f = 0.3$ (SiO_2 , 20% EtOAc/hexanes); ^1H NMR (CDCl_3 , 400 MHz): δ 7.60-7.48 (m, 2H), 7.21-7.08 (m, 2H), 4.61-4.56 (m, 1H), 4.31-4.14 (m, 3H), 3.90-3.82 (m, 1H), 3.81-3.74 (m, 1H), 3.54-3.47 (m, 1H), 3.46-3.39 (m, 1H), 2.39-2.33 (m, 2H), 2.33 (s, 3H), 1.87-1.79 (m, 1H), 1.76-1.67 (m, 5H), 1.60-1.50 (m, 4H), 1.22 (t, $J = 6.87$ Hz, 3H); ^{13}C NMR (CDCl_3 , 101 MHz): δ 172.3, 138.2, 136.9, 128.9, 126.1, 98.7, 86.9, 78.8, 72.7, 66.8, 63.2, 62.2, 30.7, 28.9, 25.4, 25.2, 21.1, 19.5, 18.6, 13.8; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{22}\text{H}_{30}\text{O}_5\text{Na}$ 397.1985; found 397.1978.

Ethyl 2,8-dihydroxy-2-(p-tolyl)oct-3-ynoate (3d): Following *General procedure D*, to a solution of ethyl 2-hydroxy-8-((tetrahydro-2H-pyran-2-yl)oxy)-2-(p-tolyl)oct-3-ynoate (**S37**) (0.1 g, 0.267 mmol) in ethanol was added *p*-toluenesulfonic acid (0.004 g, 0.027 mmol) at 0°C and then it was slowly warmed to rt to afford ethyl 2,8-dihydroxy-2-(p-tolyl)oct-3-ynoate (**3d**) (0.062 g, 80%) as a colourless liquid. TLC: $R_f = 0.4$ (SiO_2 , 40% EtOAc/hexanes); ^1H NMR (CDCl_3 , 400 MHz): δ 7.71-7.57 (m, 2H), 7.10-7.97 (m, 2H), 4.34-4.09 (m, 2H), 3.78 (s, 1H), 3.78-3.60 (m, 2H), 2.65 (s, 3H), 2.43-2.31 (m, 2H), 1.79-1.59 (m, 4H), 1.22 (t, $J = 7.33$ Hz, 3H); ^{13}C NMR (CDCl_3 , 101 MHz): δ 172.0, 135.5, 128.2, 128.1, 115.2, 114.9, 87.1, 78.7, 72.3, 63.4, 62.2, 31.7, 24.6, 18.6, 13.8; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{22}\text{O}_4\text{Na}$ 313.1410; found 313.1402.

Synthesis of **3e**:

Ethyl 2-(4-fluorophenyl)-2-hydroxy-8-((tetrahydro-2H-pyran-2-yl)oxy)oct-3-ynoate (S38): Following *General procedure B*, to a solution of 2-(hex-5-yn-1-yloxy)tetrahydro-2H-pyran (**S35**) (0.3 g, 1.64 mmol) in anhydrous THF (20 mL) under argon was added *n*-BuLi solution (1.6M in hexane, 1.54 mL, 2.46 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl 2-(4-fluorophenyl)-2-oxoacetate (**S16**) (0.39 mL, 1.97 mmol) in anhydrous THF was added at the same temperature and again stirred it for 30 min to afford ethyl 2-(4-fluorophenyl)-2-hydroxy-8-((tetrahydro-2H-pyran-2-yl)oxy)oct-3-ynoate (**S38**) (0.324 g, 52%) as a yellowish oil. TLC: R_f = 0.3 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.72-7.57 (m, 2H), 7.12-6.97 (m, 2H), 4.63-4.52 (m, 1H), 4.31-4.15 (m, 3H), 3.90-3.73 (m, 2H), 3.54-3.38 (m, 2H), 2.37 (t, J = 6.87 Hz, 2H), 1.75-1.67 (m, 5H), 1.61-1.49 (m, 5H), 1.21 (t, J = 7.33 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 172.0, 164.0, 135.6, 128.2, 128.1, 115.1, 114.9, 98.8, 87.2, 78.6, 72.3, 66.8, 63.3, 62.3, 30.7, 28.9, 25.4, 25.1, 19.5, 18.6, 13.8; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₂₁H₂₇O₅FNa 401.1735; found 401.1722.

Ethyl 2-(4-fluorophenyl)-2,8-dihydroxyoct-3-ynoate (3e): Following *General procedure D*, to a solution of ethyl 2-(4-fluorophenyl)-2-hydroxy-8-((tetrahydro-2H-pyran-2-yl)oxy)oct-3-ynoate (**S38**) (0.1 g, 8.5 mmol) in ethanol was added *p*-toluenesulfonic acid (0.008 g, 0.85 mmol) at 0 °C and then it was slowly warmed to rt to afford ethyl 2-(4-fluorophenyl)-2,8-dihydroxyoct-3-ynoate (**3e**) (0.057 g, 73%) as a colourless liquid. TLC: R_f = 0.4 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.70-7.56 (m, 2H), 7.11-6.97 (m, 2H), 4.39-4.08 (m, 2H), 3.8 (s, H), 3.69 (t, J = 5.95 Hz, 2H), 2.65 (s, 3H), 2.37 (m, 2H), 1.73-1.66 (m, 3H), 1.22 (t, J = 7.33 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 171.9, 164.03, 135.5, 128.27, 128.20, 115.17, 114.95, 87.1, 78.7, 72.3, 63.4, 62.2, 31.7, 24.6, 18.5, 13.8; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₆H₁₉O₄FNa 317.1160; found 317.1152.


Synthesis of **3f**:**Ethyl 8-((tert-butyldimethylsilyl)oxy)-2-hydroxy-2-(phenylethynyl)oct-3-ynoate (S40):**

Following *General procedure B*, to a solution of *tert*-butyl(hex-5-yn-1-yloxy)dimethylsilane¹⁷ (**S39**) (0.5 g, 2.35 mmol) in anhydrous THF (10 mL) under argon was added *n*-BuLi solution (1.6M in hexane, 2.2 mL, 3.53mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl 2-oxo-4-phenylbut-3-ynoate (**S17**) (0.571 g, 2.82mmol) in anhydrous THF was added at the same temperature and again stirred it for 30 min to afford ethyl 8-((*tert*-butyldimethylsilyl)oxy)-2-hydroxy-2-(phenylethynyl)oct-3-ynoate (**S40**) (0.18 g, 49%) as a yellowish oil. TLC: R_f = 0.7 (SiO₂, 10% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.46-7.40 (m, 2H), 7.31-7.25 (m, 3H), 4.36 (q, J = 7.13 Hz, 2H), 3.87 (br. s, 1H), 3.62-3.55 (m, 2H), 2.29-2.22 (m, 2H), 1.60-1.55 (m, 4H), 1.34 (t, J = 7.13 Hz, 3H), 0.84 (s, 9H), 0.01 (s, 6H); ¹³C NMR (CDCl₃, 126 MHz): δ 169.1, 132.0, 129.0, 128.3, 128.2, 121.7, 85.5, 85.4, 83.7, 64.0, 63.5, 61.4, 31.2, 29.7, 25.9, 25.6, 18.3, 15.2, 13.9, -5.37; HRMS (ESI) m/z : [M+H]⁺ calcd for C₂₄H₃₅O₄Si 415.2299; found 415.2294.

Ethyl 2,8-dihydroxy-2-(phenylethynyl)oct-3-ynoate(3f): Following *General procedure D*, to a solution of ethyl 8-((*tert*-butyldimethylsilyl)oxy)-2-hydroxy-2-(phenylethynyl)oct-3-ynoate (**S40**) (0.15 g, 0.36 mmol) in dry THF was added TBAF in THF (0.5 mL, 0.85 mmol) at 0 °C and then it was slowly warmed to rt to afford ethyl 2,8-dihydroxy-2-(phenylethynyl)oct-3-ynoate (**3f**) (0.1 g, 66%) as a colourless liquid. TLC: R_f = 0.4 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.51-7.44 (m, 2H), 7.35-7.29 (m, 3H), 4.41 (q, J = 7.13 Hz, 2H), 3.69 (t, J = 6.0 Hz, 2H), 2.33 (t, J = 6.75 Hz, 2H), 1.70-1.64 (m, 4H), 1.39 (t, J = 7.13 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 168.9, 132.0, 129.1, 128.23, 121.5, 85.1, 85.0, 83.7, 64.1, 63.5, 61.5, 30.6, 29.7, 15.4, 13.9; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₈H₂₁O₄ 301.1434; found 301.1421.


¹⁷Skotnitzki, J.; Kremsmair, A.; Keefer, D.; Gong, Y.; Vivie-Riedle, R. D.; Knochel, P. *Angew. Chem. Int. Ed.* **2020**, 59, 320 – 324.

Synthesis of 3g:




Ethyl 2-hydroxy-2-(naphthalene-2-yl)-8-((tetrahydro-2H-pyran-2-yl)oxy) oct-3-ynoate (S41): Following *General procedure B*, to a solution of 2-(hex-5-yn-1-yloxy)tetrahydro-2H-pyran (S35) (0.5 g, 2.74 mmol) in an anhydrous THF (20 mL) under argon was added *n*-BuLi solution (1.6 M in hexane, 2.57 mL, 4.11 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl 2-(naphthalene-2-yl)-2-oxoacetate (S19) (0.625 g, 2.74 mmol) in an anhydrous THF was added at the same temperature and stirred it for 30 min to afford ethyl 2-hydroxy-2-(naphthalene-2-yl)-8-((tetrahydro-2H-pyran-2-yl)oxy) oct-3-ynoate (S41) (0.3g, 45% brsm) as yellowish oil. TLC: R_f = 0.4 (SiO₂, 30% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 8.27-8.06 (m, 2H), 7.97-7.77 (m, 2H), 7.59-7.36 (m, 3H), 4.61 (s, 1H), 4.30-4.13 (m, 2H), 3.92-3.76 (m, 2H), 3.58-3.34 (m, 2H), 2.52-2.39 (t, J = 6.7 Hz, 2H), 1.88-1.67 (m, 6H), 1.62-1.50 (m, 4H), 1.08 (t, J = 7.3 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 173.1, 134.3, 133.9, 130.4, 130.1, 128.9, 127.2, 126.4, 125.7, 124.8, 98.9, 89.6, 78.9, 74.5, 67.0, 63.2, 62.4, 30.8, 29.1, 25.5, 25.3, 19.7, 18.9, 13.8; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₂₅H₃₀O₅Na 433.1985; found 433.1973.

Ethyl 2,8-dihydroxy-2-(naphthalene-2-yl) oct-3-ynoate (3g): Following *General procedure D*, to a solution of ethyl 2-hydroxy-2-(naphthalene-2-yl)-8-((tetrahydro-2H-pyran-2-yl)oxy) oct-3-ynoate (S41) (0.3g, 7.3 mmol) in ethanol (5 mL) was added *p*-toluenesulfonic acid (0.14 g, 7.3 mmol) at 0 °C and then it was slowly warmed to rt to afford ethyl 2,8-dihydroxy-2-(naphthalene-2-yl) oct-3-ynoate (3g) (0.15 g, 63%) as a colourless liquid. TLC: R_f = 0.3 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 8.21-8.1 (m, 2H), 7.91-7.81 (m, 2H), 7.53-7.44 (m, 3H), 4.29-4.11 (m, 3H), 3.75-3.67 (m, 2H), 2.47-2.41 (m, 2H), 1.76-1.7 (m, 4H), 1.09 (t, J = 7.25 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 173.1, 134.3, 133.9, 130.3, 130.1, 128.9, 127.1, 126.3, 125.6, 124.7, 89.4, 79.05, 74.5, 63.2, 62.3, 31.8, 24.6, 18.8, 13.7; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₂₀H₂₂O₄Na 349.1410; found 349.1405.

Synthesis of **3k**:


Ethyl 2-hydroxy-2-(1-methyl-1*H*-indol-3-yl)-8-((tetrahydro-2*H*-pyran-2-yl)oxy)oct-3-ynoate (3k**):** Following *General procedure B*, to a solution of 2-(hex-5-yn-1-yloxy)tetrahydro-2*H*-pyran (**S35**) (0.5 g, 2.74 mmol) in anhydrous THF (10 mL) under argon was added *n*-BuLi solution (1.6 M in hexane, 2.6 mL, 4.11 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl 2-(1-methyl-1*H*-indol-3-yl)-2-oxoacetate (**S20**) (0.761 g, 3.29 mmol) in anhydrous THF was added at the same temperature and stirred it for 30 min to afford ethyl 2-hydroxy-2-(1-methyl-1*H*-indol-3-yl)-8-((tetrahydro-2*H*-pyran-2-yl)oxy)oct-3-ynoate (**3k**) (0.67g, 59%) as a yellowish oil. TLC: R_f = 0.3 (SiO₂, 30% EtOAc /hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.77-7.68 (m, 1H), 7.36-7.33 (m, 1H), 7.32-7.28 (m, 1H), 7.25-7.20 (m, 1H), 7.15-7.09(m, 1H), 4.62-4.56 (m, 1H), 4.37-4.14 (m, 2H), 3.91-3.84 (m, 2H), 3.78 (s, 3H), 3.52-3.42 (m, 2H), 2.38 (t, J = 7.0 Hz, 2H), 1.91-1.45 (m, 10H), 1.22 (t, J = 7.13 Hz, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 172.5, 137.7, 128.5, 124.9, 121.9, 120.3, 119.6, 114.2, 109.4, 98.9, 85.6, 79.0, 69.0, 67.0, 63.2, 62.3, 32.9, 30.7, 29.0, 25.5, 25.3, 19.6, 18.7, 14.0; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₂₄H₃₁O₅NNa 436.2094; found 436.2096.

Synthesis of **3h**:

Ethyl 2,8-dihydroxy-2-methylnon-3-ynoate (3h**):** Following *General procedure A*, a solution of hept-6-yn-2-ol(**S8**) (0.2 g, 2.04 mmol) and ethyl pyruvate (**S11**) (0.71 g, 6.1 mmol) in 3 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.016 g, 0.061 mmol, 3.0 mol%) and JohnPhos (0.055g, 0.18 mmol, 9.0 mol%) under argon to ethyl 2,8-dihydroxy-2-methyloct-3-ynoate (**3h**) (0.119g, 52%) as a colourless liquid. TLC: R_f = 0.2 (SiO₂, 40% EtOAc/hexanes); ¹H NMR


(CDCl₃, 500 MHz): δ 4.28 (q, J = 6.87 Hz, 2H), 3.87-3.763 (m, 1H), 3.45 (s, 1H), 2.25 (t, J = 6.87 Hz, 2H), 1.53 (s, 3H), 1.6-1.43 (m, 4H), 1.33 (t, J = 7.63 Hz, 3H), 1.17 (d, J = 6.87 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 173.2, 84.7, 80.3, 68.0, 67.7, 62.8, 38.3, 27.5, 24.6, 23.7, 18.7, 14.1; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₂H₂₀O₄Na 251.1254; found 251.1245.

Synthesis of 3i:



Ethyl 2,8-dihydroxy-2-phenylnon-3-ynoate (3i): Following *General procedure A*, a solution of hept-6-yn-2-ol (**S8**) (0.3 g, 2.67 mmol) and ethyl phenyl glyoxylate (**S12**) (1.4 g, 8.02 mmol) in 5 mL of THF was added to a mixture of Rh(acac)(CO)₂ (0.02 g, 0.080 mmol, 3 mol%) and JohnPhos (0.071 g, 2.4 mmol, 9 mol%) under argon to obtain ethyl 2,8-dihydroxy-2-phenylnon-3-ynoate (**3i**) (0.24 g, 22%; 54% brsm) as a colourless liquid. TLC: R_f = 0.2 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.74-7.58 (m, 2H), 7.41-7.3 (m, 3H), 4.33-4.08 (m, 3H), 3.89-3.80 (m, 1H), 2.4-2.32 (m, 2H), 1.78-1.48 (m, 4H), 1.29-1.16 (m, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 172.3, 139.8, 128.5, 128.2, 126.2, 87.0, 78.9, 72.9, 67.6, 67.06, 63.3, 38.3, 30.3, 24.6, 23.6, 18.8, 18.7, 13.8, 13.5; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₇H₂₂O₄Na 313.1410; found 313.1404.


Synthesis of 5b:



Ethyl 8-((tert-butyldimethylsilyl)oxy)-2-hydroxy-2-methyldodec-3-ynoate (5b): Following *General procedure C*, to a solution of tert-butyl(dec-9-yn-5-yloxy)dimethylsilane (**S42**) (0.5 g, 1.86 mmol) in an anhydrous THF (20 mL) under argon was added *n*-BuLi solution (1.6 M in

hexane, 1.74 mL, 2.79 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl pyruvate (**S11**) (0.26 g, 2.23mmol) in an anhydrous THF was added at the same temperature and stirred it for 30 min to afford ethyl 8-((*tert*-butyldimethylsilyl)oxy)-2-hydroxy-2-methyldodec-3-ynoate (**5b**) (0.427 g, 60%) as yellowish oil. TLC: R_f = 0.4 (SiO₂, 10% EtOAc /hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 4.28(q, J = 6.87 Hz, 2H), 3.67-3.55 (m, 1H), 2.25-2.16 (m, 2H), 1.64 (s, 3H), 1.56-1.39 (m, 7H), 1.35-1.24 (m, 7H), 0.87 (s, 12H), 0.03 (s, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 173.1, 84.8, 79.9, 71.7, 67.8, 6.6, 36.7, 36.0, 30.4, 27.4, 27.3, 25.8, 24.05, 22.8, 18.8, 18.06, 14.06, 13.9, -4.5; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₂₁H₄₀O₄NaSi 407.2588; found 407.2580.

Synthesis of **3j**:




Triethyl((2-methylhept-6-yn-2-yl)oxy)silane (S43**):** To a solution of 2-methylhept-6-yn-2-ol (**S10**) (1.6 g, 12.67 mmol) in anhydrous DMF (15 mL) under argon was added imidazole (1.72 g, 25.34 mmol) and chlorotriethylsilane (4.7 mL, 13.16 mmol) was added at 0 °C. The resultant reaction mixture was warmed to rt and monitored by TLC, then the reaction was quenched with ice-cold water and extracted with diethyl ether to afford triethyl((2-methylhept-6-yn-2-yl)oxy)silane (**S43**) (1.8 g, 56%). TLC: R_f = 0.8 (SiO₂, 10% EtOAc/hexanes) as a yellow oil; ¹H NMR (CDCl₃, 400 MHz): δ 2.22-2.15 (m, 2H), 1.96-1.91 (m, 1H), 1.62-1.49 (m, 4H), 1.21 (s, 6H), 0.96-0.92 (m, 9H), 0.61-0.54 (m, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 84.8, 73.1, 68.1, 44.2, 29.9, 23.6, 18.9, 7.1, 6.8, 6.4; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₄H₂₉OSi 241.1982; found 241.1983.

Ethyl 2-hydroxy-2,8-dimethyl-8-((triethylsilyl)oxy)non-3-ynoate (5c**):** To a solution of triethyl((2-methylhept-6-yn-2-yl)oxy)silane (**S43**) (0.3 g, 1.25 mmol) in anhydrous THF (10 mL) under argon was added *n*-BuLi solution (1.6 M in hexane, 1.19 mL, 1.9 mmol). The resultant mixture was stirred at -78 °C for 45 min. Then the solution of ethyl pyruvate (**S11**) (0.18 g, 1.5 mmol) in anhydrous THF was added at the same temperature and again stirred it for 30 min to

afford ethyl 2-hydroxy-2,8-dimethyl-8-((triethylsilyl)oxy)non-3-ynoate(**5c**)(0.32 g, 73%). TLC: R_f = 0.5 (SiO₂, 20% EtOAc/hexanes) as a yellowish oil; ¹H NMR (CDCl₃, 400 MHz): δ 4.30 (q, J = 7.13 Hz, 2H), 3.42(s, 1H), 2.20 (d, J = 6.88 Hz, 2H), 1.66 (s, 3H), 1.59-1.47 (m, 4H), 1.34 (t, J = 7.13 Hz, 3H), 1.20 (s, 6H), 0.94 (t, J = 8.0 Hz, 9H), 0.57 (q, J = 7.75 Hz, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 173.2, 85.1, 79.9, 73.1, 67.9, 62.7, 44.2, 29.9, 27.3, 23.4, 19.1, 14.0, 7.12, 6.7; HRMS (ESI) m/z : $[M+Na]^+$ calcd for C₁₉H₃₆O₄NaSi 379.2275; found 379.2270.

Ethyl 2,8-dihydroxy-2,8-dimethylnon-3-ynoate (3j):Following *General procedure D*, to a solution of ethyl 2-hydroxy-2,8-dimethyl-8-((triethylsilyl)oxy)non-3-ynoate (**S43**) (0.15 g, 0.36 mmol) in dry THF was added TBAF in THF (0.5 mL, 0.85 mmol) at 0 °C and then it was slowly warmed to rt to afford ethyl 2,8-dihydroxy-2,8-dimethylnon-3-ynoate (**3j**) (0.1 g, 66%) as a colourless liquid. TLC: R_f = 0.7 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 4.3 (q, J = 7.13 Hz, 2H), 2.23(t, J = 6.63 Hz, 2H), 1.66 (s, 3H), 1.62-1.52 (m, 4H), 1.34 (t, J = 7.13Hz, 3H), 1.22 (s, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 173.1, 84.7, 80.2, 76.7, 70.8, 67.9, 62.7, 42.9, 29.3, 27.4, 23.4, 19.1, 14.04; HRMS (ESI) m/z : $[M+Na]^+$ calcd for C₁₃H₂₂O₄Na 265.1410; found 265.1411.


6. Synthesis of [5,5]-unsaturated oxaspirolactones from propargylic diol esters



General Procedure F for the synthesis of [5,5] and [6,5]- α,β -unsaturated oxaspirolactones (**2** and **4**) from propargylic diol esters (**1** and **3**): To a stirred solution of **1** or **2** (0.25 mmol) in anhydrous CH₂Cl₂ (2.0 mL) was added Bi(OTf)₃ (0.024 mmol, 10 mol%) at room temperature under argon atmosphere, and the reaction mixture was stirred at rt until complete conversion monitored by TLC. The reaction was quenched by the addition of saturated aqueous solution of NaHCO₃. The resulting mixture was extracted with CH₂Cl₂ (2x5 mL) and combined organic layers were washed with brine solution. The combined extracts were dried over an anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by


silica gel column chromatography (elution with EtOAc/hexanes) to afford [5,5] or [6,5]- α,β -unsaturated oxaspirolactones (**2** or **4**).

3-Methyl-1, 14-dioxadispiro [4.1.5⁷.2⁵] tetradec-3-en-2-one (**2a**):




Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclohexyl)-2-methylpent-3-ynoate (**1a**) (0.05 g, 0.19 mmol) in an anhydrous CH₂Cl₂ (1.0 mL) was added Bi(OTf)₃ (0.012 g, 0.019 mmol) under argon atmosphere to obtain 3-methyl-1, 14-dioxadispiro [4.1.5⁷.2⁵] tetradec-3-en-2-one (**2a**) (0.035 g, 85%) as a colourless liquid. TLC: R_f = 0.7 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 6.69-6.67 (m, 1H), 3.95 (d, J = 8.39 Hz, 1H), 3.86 (d, J = 8.39 Hz, 1H), 2.12 (d, J = 14.5 Hz, 1H), 2.01 (d, J = 14.5 Hz, 1H), 1.91 (s, 3H), 1.72-1.64 (m, 2H), 1.53-1.38 (m, 8H); ¹³C NMR (CDCl₃, 101 MHz): δ 171.6, 145.1, 132.5, 113.2, 80.4, 47.1, 43.6, 37.4, 35.5, 25.6, 23.8, 23.7, 10.4; FTIR (cm⁻¹) 2928, 2857, 1767, 1669, 1447, 1329, 1123, 1008, 972, 870, 763; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₃H₁₉O₃ 223.1329; found 223.1333.


3-Phenyl-1, 14-dioxadispiro [4.1.5⁷.2⁵] tetradec-3-en-2-one (**2b**):




Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclohexyl)-2-phenylpent-3-ynoate (**1b**) (0.05 g, 0.15 mmol) in an anhydrous CH₂Cl₂ (2 mL) was added Bi(OTf)₃ (0.01 g, 0.015 mmol) under argon atmosphere to obtain 3-phenyl-1,14-dioxadispiro[4.1.5⁷.2⁵]tetradec-3-en-2-one (**2b**) (0.035 g, 81%). TLC: R_f = 0.7 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.91-7.75 (m, 2H), 7.5-7.37 (m, 3H), 7.17 (s, 1H), 4.04(d, J = 8.46 Hz, 1H), 3.93 (d, J = 8.46 Hz, 1H), 2.24 (d, J = 13.89 Hz, 1H), 2.13(d, J = 13.77 Hz, 1H), 1.81-1.68 (m, 2H), 1.64-1.39 (m, 8H); ¹³C NMR (CDCl₃, 101 MHz): δ 169.3, 143.7, 133.6, 129.7, 129, 128.7, 127.5, 112.4, 80.5, 47.4, 43.8, 37.4, 35.5, 25.6, 23.9, 23.8; FTIR (cm⁻¹) 3023, 2928, 2858, 1761, 1647, 1451, 1216, 1123, 1037, 944, 847, 762, 671; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₈H₂₁O₃ 285.1485; found 285.1483.

3-(4-Methoxyphenyl)-1,14-dioxadispiro[4.1.5⁷.2⁵]tetradec-3-en-2-one (2c):

Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclohexyl)-2-(4-methoxyphenyl) pent-3-ynoate (**1c**) (0.1 g, 0.277 mmol) in anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.018g, 0.0277mmol) under argon atmosphere to obtain 3-(4-methoxyphenyl)-1,14-dioxadispiro[4.1.5⁷.2⁵]tetradec-3-en-2-one (**2c**) (0.072 g, 83%). TLC: *R_f* = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.91-7.75 (m, 2H), 7.06 (s, 1H), 7.04-6.92 (m, 2H), 4.04(d, *J* = 8.46 Hz, 1H), 3.93 (d, *J* = 8.46 Hz, 1H), 3.86 (s, 3H), 2.24 (d, *J* = 13.89 Hz, 1H), 2.13(d, *J* = 13.77 Hz, 1H), 1.81-1.68 (m, 2H), 1.64-1.39 (m, 8H); ¹³C NMR (CDCl₃, 101 MHz): δ 169.6, 160.7, 141.3, 132.9, 129.0, 121.5, 114.1, 112.4, 80.5, 55.4, 47.4, 43.8, 37.4, 35.6, 25.6, 23.87, 23.76; FTIR (cm⁻¹) 3022, 2927, 2856, 1761, 1610, 1512, 1455, 1252, 1216, 1171, 1124, 1033, 909, 838, 761, 666; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₉H₂₃O₄ 315.1591; found 315.1582.

3-(*p*-tolyl)-1,14-dioxadispiro[4.1.5⁷.2⁵]tetradec-3-en-2-one (2d):


Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclohexyl)-2-(*p*-tolyl)pent-3-ynoate (**1d**) (0.05 g, 0.15 mmol) in an anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.009, 0.015 mmol) under argon atmosphere to obtain 3-(*p*-tolyl)-1,14-dioxadispiro[4.1.5⁷.2⁵]tetradec-3-en-2-one (**2d**) (0.034 g, 79%). TLC: *R_f* = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.76-7.70 (m, 2H), 7.23-7.18 (m, 2H), 7.11 (s, 1H), 4.0 (d, *J* = 8.46 Hz, 1H), 3.91 (d, *J* = 8.46 Hz, 1H), 2.36 (s, 3H), 2.21 (d, *J* = 13.89 Hz, 1H), 2.12 (d, *J* = 13.77 Hz, 1H), 1.74-1.69 (m, 2H), 1.56-1.42 (m, 8H); ¹³C NMR (CDCl₃, 101 MHz): δ 169.4, 142.6, 139.8, 133.3, 129.3, 127.3, 126.0, 112.3, 80.4, 47.3, 43.7, 37.3, 35.5, 25.5, 23.8, 23.7, 21.3; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₉H₂₃O₃ 299.1642; found 299.1643.

3-(Phenylethynyl)-1,14-dioxadispiro[4.1.5⁷.2⁵]tetradec-3-en-2-one (2e):

Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclohexyl)-2-(phenylethynyl)pent-3-ynoate (**1e**) (0.1 g, 0.282 mmol) in an anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.018 g, 0.028 mmol) under argon atmosphere to obtain 3-(phenylethynyl)-1,14-


dioxadispiro[4.1.5^{7.25}]tetradec-3-en-2-one] (**2e**) (0.071 g, 82%). TLC: R_f = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.57-7.52 (m, 2H), 7.4-7.34 (m, 3H), 7.14-7.09 (m, 1H), 4.01(d, J = 8.39 Hz, 1H), 3.92 (d, J = 8.39 Hz, 1H), 2.21 (d, J = 13.73 Hz, 1H), 2.1(d, J = 13.73 Hz, 1H), 1.73-1.68 (m, 2H), 1.53-1.44 (m, 8H); ¹³C NMR (CDCl₃, 101 MHz): δ 167.3, 150.4, 133.8, 132.1, 129.6, 128.4, 121.5, 120.1, 113.8, 97.9, 80.8, 78.1, 43.8, 37.3, 35.5, 25.5, 23.9, 23.7; HRMS (ESI) m/z : $[M+H]^+$ calcd for C₂₀H₂₁O₃ 309.1485; found 309.1483.

3-Methyl-1, 13-dioxadispiro [4.1.4^{7.25}] tridec-3-en-2-one (**2f**):



Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-methylpent-3-ynoate (**1f**) (0.05 g, 0.2 mmol) in anhydrous CH₂Cl₂ (1 mL) was added Bi(OTf)₃ (0.013 g, 0.02 mmol) under argon atmosphere to obtain 3-methyl-1, 13-dioxadispiro [4.1.4^{7.25}] tridec-3-en-2-one (**2f**) (0.032 g, 78%) as white solid. TLC: R_f = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 6.71 (s, 1H), 4.01(d, J = 8.4 Hz, 1H), 3.85 (d, J = 8.4 Hz, 1H), 2.18 (s, 2H), 1.92 (s, 3H), 1.86-1.81(m, 2H), 1.7-1.58 (m, 6H); ¹³C NMR (CDCl₃, 126 MHz): δ 171.6, 145.1, 132.5, 113.3, 81.1, 50.3, 47.4, 38.01, 37.2, 24.6, 24.4, 10.4; FTIR (cm⁻¹) 3020, 2931, 2866, 1764, 1659, 1447, 1397, 1330, 1222, 1115, 1006, 758, 672; HRMS (ESI) m/z : $[M+H]^+$ calcd for C₁₂H₁₇O₃ 209.1172; found 209.1176.


3-Phenyl-1, 13-dioxadispiro [4.1.4^{7.25}] tridec-3-en-2-one (**2g**):



Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-phenylpent-3-ynoate(**1g**) (0.05 g, 1.6 mmol) in anhydrous CH₂Cl₂ (1 mL) was added Bi(OTf)₃ (0.0103 g, 0.016 mmol) under argon atmosphere to obtain 3-phenyl-1, 13-dioxadispiro [4.1.4^{7.25}] tridec-3-en-2-one (**2g**) (0.37 g, 86 %) as a white solid; TLC: R_f = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.88-7.8 (m, 2H), 7.46-7.37 (m, 3H), 7.19 (s, 1H), 4.08 (d, J = 8.1 Hz, 1H), 3.92 (d, J = 8.39 Hz, 1H), 2.4-2.2 (m, 2.37-2.25 (m, 2H), 1.93-1.84 (m, 2H), 1.79-1.62 (m, 6H); ¹³C NMR (CDCl₃, 126 MHz): δ 169.3, 143.7, 133.6, 129.7, 129.0, 128.7, 127.6, 112.4, 81.3, 50.5, 47.7, 38.01, 37.2, 24.7,24.4; FTIR (cm⁻¹) 3023, 2955, 2403,


1763, 1647, 1439, 1334, 1216, 1116, 1034, 942, 852, 760, 669; HRMS (ESI) m/z : $[M+H]^+$ calcd for $C_{17}H_{19}O_3$ 271.1329; found 271.1333.

3-(4-Nitrophenyl)-1, 13-dioxadispiro [4.1.4⁷.2⁵] tridec-3-en-2-one (**2h**):




Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-(4-nitrophenyl)pent-3-ynoate (**1h**) (0.05 g, 0.14 mmol) in anhydrous CH_2Cl_2 (1 mL) was added $Bi(OTf)_3$ (0.009 g, 0.014 mmol) under argon atmosphere to obtain 3-(4-nitrophenyl)-1, 13-dioxadispiro [4.1.4⁷.2⁵] tridec-3-en-2-one (**2h**) (0.032 g, 73%) as a yellowish solid. TLC: R_f = 0.6 (SiO_2 , 20% EtOAc/hexanes); 1H NMR ($CDCl_3$, 400 MHz): δ 8.28 (d, J = 8.5 Hz, 2H), 8.06 (d, J = 9.2 Hz, 2H), 7.39 (s, 1H), 4.11 (d, J = 8.5 Hz, 1H), 3.94 (d, J = 7.9 Hz, 1H), 2.39-2.27 (m, 2H), 1.95-1.83 (m, 2H), 1.81-1.62 (m, 6H); ^{13}C NMR ($CDCl_3$, 101 MHz): δ 168.3, 148.3, 147.0, 135.0, 131.7, 128.5, 123.9, 112.6, 81.5, 50.6, 47.6, 37.9, 37.1, 24.6, 24.4; FTIR (cm^{-1}) 3023, 2949, 1756, 1650, 1521, 1350, 1215, 1350, 1215, 1118, 1047, 760; HRMS (ESI) m/z : $[M+H]^+$ calcd for $C_{17}H_{18}O_5N$ 316.1179; found 316.1187.


3-(1*H*-Indol-3-yl)-1,13-dioxadispiro[4.1.4⁷.2⁵]tridec-3-en-2-one (**2i**):




Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(1-(hydroxymethyl) cyclopentyl)-2-(1-methyl-1*H*-indol-3-yl) pent-3-ynoate (**1i**) (0.012 g, 0.034 mmol) in anhydrous CH_2Cl_2 (1 mL) was added $Bi(OTf)_3$ (0.002 g, 0.003 mmol) under argon atmosphere to obtain 3-(1-methyl-1*H*-indol-3-yl)-1, 13-dioxadispiro [4.1.4⁷.2⁵] tridec-3-en-2-one (**2i**) (0.0074 g, 71%) as a yellowish solid. TLC: R_f = 0.3 (SiO_2 , 20% EtOAc/hexanes); 1H NMR ($CDCl_3$, 400 MHz): δ 8.5 (br. s, 1H), 8.32-8.21 (m, 1H), 7.85-7.73 (m, 1H), 7.50-7.40 (m, 1H), 7.3-7.2 (m, 2H), 7.18 (s, 1H), 4.09 (d, J = 8.39 Hz, 1H), 3.93 (d, J = 7.63 Hz, 1H), 2.34 (dd, J = 12.97, 2.29 Hz, 2H), 1.94-1.84 (m, 2H), 1.8-1.65 (m, 6H); ^{13}C NMR ($CDCl_3$, 101 MHz): δ 170.8, 136.4, 136.2, 128.0, 127.2, 125.6, 123.0, 121.1, 119.7, 114.0, 111.8, 105.9, 81.1, 64.5, 50.4, 48.0, 38.2, 37.3, 24.7, 24.4; HRMS (ESI) m/z : $[M+H]^+$ calcd for $C_{19}H_{20}O_3N$ 310.1438; found 310.1438.

3,8,8-Trimethyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2j):

Following *General Procedure F*, to the mixture of ethyl 2,7-dihydroxy-2,6,6-trimethylhept-3-ynoate (**1j**) (0.1 g, 0.44 mmol) in an anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.029 g, 0.044 mmol) under argon atmosphere to obtain 3,8,8-trimethyl-1,6-dioxaspiro[4.4]non-3-en-2-one (**2j**) (0.068 g, 86%) as a yellowish oil. TLC: *R_f* = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 6.63 (s, 1H), 3.8 (d, *J* = 8.39 Hz, 1H), 3.66 (d, *J* = 8.39 Hz, 1H), 1.99 (s, 2H), 1.81 (s, 3H), 1.18 (s, 3H), 1.09 (s, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 171.3, 145.2, 131.8, 113.4, 81.8, 48.8, 39.3, 27.5, 25.9, 10.1; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₀H₁₅O₃ 183.1016; found 183.1015.

8,8-Dimethyl-3-phenyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2k):


Following *General Procedure F*, to the mixture of ethyl 2,7-dihydroxy-6,6-dimethyl-2-phenylhept-3-ynoate (**1k**) (0.1 g, 0.34 mmol) in an anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.023 g, 0.034 mmol) under argon atmosphere to obtain 8,8-dimethyl-3-phenyl-1,6-dioxaspiro[4.4]non-3-en-2-one (**2k**) (0.071 g, 84%) as a white solid. TLC: *R_f* = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.86-7.77 (m, 2H), 7.43-7.33 (m, 3H), 7.16 (s, 1H), 3.96 (d, *J* = 8.39 Hz, 1H), 3.8 (d, *J* = 8.39 Hz, 1H), 2.19 (s, 2H), 1.31 (s, 3H), 1.22 (s, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 169.2, 143.8, 133.3, 129.7, 128.9, 128.6, 127.5, 112.7, 82.2, 49.4, 39.7, 27.8, 26.1; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₅H₁₇O₃ 245.1172; found 245.1172.

3-(4-Methoxyphenyl)-8,8-dimethyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2l):

Following *General Procedure F*, to the mixture of ethyl 2,7-dihydroxy-2-(4-methoxyphenyl)-6,6-dimethylhept-3-ynoate (**1l**) (0.05 g, 0.15 mmol) in an anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.010 g, 0.015 mmol) under argon atmosphere to obtain 3-(4-methoxyphenyl)-8,8-dimethyl-1,6-dioxaspiro[4.4]non-3-en-2-one (**2l**) (0.038 g, 90%) as a white


solid. TLC: R_f = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.89-7.76 (m, 2H), 7.06 (s, 1H), 6.97-6.85 (m, 2H), 3.97 (d, J = 8.24 Hz, 1H), 3.84 (s, 3H), 3.81 (d, J = 8.24 Hz, 1H), 2.23- 2.14 (m, 2H), 1.32 (s, 3H), 1.23 (s, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 169.5, 160.7, 141.4, 132.7, 128.9, 121.4, 114.0, 112.7, 82.1, 55.3, 49.5, 39.7, 27.9, 26.2; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₆H₁₉O₄ 275.1278; found 275.1274.

8,8-Dimethyl-3-(*p*-tolyl)-1,6-dioxaspiro[4.4]non-3-en-2-one(2m):




Following *General Procedure F*, to the mixture of ethyl 2,7-dihydroxy-6,6-dimethyl-2-(*p*-tolyl)hept-3-ynoate (**1m**) (0.08g, 0.26 mmol) in an anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.017 g, 0.026 mmol) under argon atmosphere to obtain 8,8-dimethyl-3-(*p*-tolyl)-1,6-dioxaspiro[4.4]non-3-en-2-one (**2m**) (0.054 g, 80%) as a white solid. TLC: R_f = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.74-7.69 (m, 2H), 7.2-7.15 (m, 2H), 7.11(s, 1H), 3.93 (d, J = 8.39 Hz, 1H), 3.78 (d, J = 8.39 Hz, 1H), 2.34 (s, 3H), 2.15 (s, 2H), 1.29 (s, 3H), 1.19 (s, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 169.3, 142.8, 139.7, 132.9, 129.2, 127.2, 125.9, 112.6, 82.0, 49.2, 39.6, 27.6, 26.0, 21.2; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₆H₁₉O₃ 259.1329; found 259.1328.


3-(4-Fluorophenyl)-8,8-dimethyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2n):




Following *General Procedure F*, to the mixture of ethyl 2-(4-fluorophenyl)-2,7-dihydroxy-6,6-dimethylhept-3-ynoate (**1n**) (0.07 g, 0.23 mmol) in an anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.0145 g, 0.023mmol) under argon atmosphere to obtain 8,8-dimethyl-3-(4-nitrophenyl)-1,6-dioxaspiro[4.4]non-3-en-2-one (**2n**) (0.041g, 77%) as a white solid. TLC: R_f = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.90-7.79 (m, 2H), 7.16-7.06 (m, 3H), 3.98 (d, J = 8.39 Hz, 1H), 3.82 (d, J = 8.39 Hz, 1H), 2.26-2.15 (m, 2H), 1.33 (s, 3H), 1.24 (s, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 169.1, 163.6 (J = 251 Hz), 143.3 (J = 1.53 Hz), 132.3, 129.6 (J = 8.39 Hz), 125.1 (J = 3.05 Hz), 115.8 (J = 23.36 Hz), 112.7, 82.3, 49.4, 39.8, 27.9, 26.2; ¹⁹F NMR (CDCl₃, 376 MHz): δ -110.4 ; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₅H₁₆FO₃ 263.1078; found 263.1082.

3-Methyl-1, 6-dioxaspiro [4.4] non-3-en-2-one (2o):

Following *General Procedure F*, to the mixture of ethyl 2,7-dihydroxy-2-methylhept-3-ynoate(**1o**)(0.05 g, 0.25 mmol) in anhydrous CH₂Cl₂ (1 mL) was added Bi(OTf)₃ (0.0164 g ,0.025 mmol) under argon atmosphere to obtain 3-methyl-1, 6-dioxaspiro [4.4] non-3-en-2-one (**2o**) (0.27 g, 71 %) as a yellowish oil. TLC: R_f = 0.3 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 6.74-6.67 (m, 1H), 4.24-4.17 (m, 1H), 4.08-4.01 (m, 1H), 2.35-2.08 (m, 4H), 1.91 (s, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 171.3, 144.3, 133.2, 112.6, 70.2, 35.2, 24.1, 10.4; FTIR (cm⁻¹) 3023, 2928, 2404, 1729, 1655, 1452, 1263, 1216, 1050, 844, 760, 670; HRMS (ESI) m/z : [M+H]⁺ calcd for C₈H₁₁O₃ 155.0703; found 155.1313.

3-Methyl-1, 6-dioxaspiro [4.4] non-3-en-2-one (2o):


Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-7-((4-methoxybenzyl)oxy)-2-methylhept-3-ynoate (**5f**) (1g, 3.12 mmol) in anhydrous CH₂Cl₂ (10 mL) was added Bi(OTf)₃ (0.204 g , 0.31mmol) under argon atmosphere to obtain 3-methyl-1, 6-dioxaspiro [4.4] non-3-en-2-one (**2o**) (0.340 g, 71 %) as a yellowish oil. TLC: R_f = 0.3 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400MHz): δ 6.77-6.65(m, 1H), 4.23-4.16 (m, 1H), 4.13-3.97(m, 1H), 2.39-2.05 (m, 4H), 1.93 (s, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 171.4, 144.3, 133.4, 112.7, 70.3, 35.3, 24.2, 10.6.

3-methyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2o):

The reaction of 2N-HCl (1.5 equiv) with 3-methyl-1, 6-dioxaspiro [4.4] non-3-en-2-one (2o): To the mixture of 3-methyl-1, 6-dioxaspiro [4.4] non-3-en-2-one (**2o**) (0.1 g, 3.12 mmol) in anhydrous CH₂Cl₂ (2 mL) was added 2N HCl (0.5 mL , 0.97 mmol) under argon atmosphere and stirred for 12 h, no conversion was observed through TLC monitoring. Hence, quenched with saturated aqueous NaHCO₃ solution and extracted with anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to obtain the crude product. Purification by silica-gel column chromatography gave unreacted 3-methyl-1, 6-dioxaspiro [4.4] non-3-en-2-one (**2o**) (0.091 g, 91 %) as a yellowish oil. TLC: R_f = 0.3 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 6.77-6.65 (m, 1H), 4.23-4.16 (m, 1H), 4.13-3.97 (m, 1H), 2.39-2.05 (m, 4H), 1.93 (s, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 171.4,


144.3, 133.4, 112.7, 70.3, 35.3, 24.2, 10.6; HRMS (ESI) m/z : $[M+H]^+$ calcd for $C_8H_{11}O_3$ 155.0703; found 155.1313.

3-Phenyl-1, 6-dioxaspiro [4, 4] non-3-en-2-one (2p):




Following *General Procedure F*, to the mixture of ethyl 2,7-dihydroxy-2-phenylhept-3-ynoate (**1p**) (1.0 g, 3.81 mmol) in an anhydrous CH_2Cl_2 (10 mL) was added $Bi(OTf)_3$ (0.250 g, 0.38 mmol) under argon atmosphere to obtain 3-phenyl-1, 6-dioxaspiro [4, 4] non-3-en-2-one (**2p**) (0.62 g, 75%) as a yellow oil. TLC: R_f = 0.6 (SiO_2 , 20% EtOAc/hexanes); 1H NMR ($CDCl_3$, 400 MHz): δ 7.92-7.76 (m, 2H), 7.50-7.36 (m, 3H), 7.21 (s, 1H), 4.37-4.25 (m, 1H), 4.20-4.05 (m, 1H), 2.47-2.10 (m, 4H); ^{13}C NMR ($CDCl_3$, 101 MHz): δ 169.1, 142.9, 134.4, 129.8, 129.0, 128.7, 127.5, 111.9, 70.5, 35.5, 24.3; FTIR (cm^{-1}) 3074, 2976, 2899, 1762, 1643, 1590, 1491, 1449, 1340, 1231, 1175, 1094, 1017, 955, 932, 876, 756, 695, 658; HRMS (ESI) m/z : $[M+H]^+$ calcd for $C_{13}H_{13}O_3$ 217.0859; found 217.0864.

3-(*p*-Tolyl)-1,6-dioxaspiro[4.4]non-3-en-2-one(2q):




Following *General Procedure F*, to the mixture of ethyl 2,7-dihydroxy-2-(*p*-tolyl)hept-3-ynoate (**1q**) (0.1 g, 0.36 mmol) in anhydrous CH_2Cl_2 (5 mL) was added $Bi(OTf)_3$ (0.023 g, 0.036 mmol) under argon atmosphere to obtain 3-(*p*-tolyl)-1,6-dioxaspiro[4.4]non-3-en-2-one (**2q**) (0.065 g, 78%) as a yellow solid. TLC: R_f = 0.6 (SiO_2 , 20% EtOAc/hexanes); 1H NMR ($CDCl_3$, 500 MHz): δ 7.75 (d, J = 8.13 Hz, 2H), 7.22 (d, J = 8 Hz, 2H), 7.15 (s, 1H), 4.33-4.24 (m, 1H), 4.16-4.07 (m, 1H), 2.38 (s, 3H), 2.36-2.15 (m, 4H); ^{13}C NMR ($CDCl_3$, 126 MHz): δ 169.3, 141.9, 140, 134.2, 129.4, 127.4, 126.2, 111.8, 70.4, 35.7, 24.3, 21.4; HRMS (ESI) m/z : $[M+H]^+$ calcd for $C_{14}H_{15}O_3$ 231.1016; found 231.1019.

3-(4-Methoxyphenyl)-7-methyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2r):


Following *General Procedure F*, to the mixture of ethyl 2,7-dihydroxy-2-(4-methoxyphenyl)oct-3-ynoate (**1r**) (0.05 g, 0.16 mmol) in an anhydrous CH_2Cl_2 (5 mL) was added $\text{Bi}(\text{OTf})_3$ (0.01 g, 0.016 mmol) under argon atmosphere to obtain 3-(4-methoxyphenyl)-7-methyl-1,6-dioxaspiro[4.4]non-3-en-2-one (**2r**)

(0.38 g, 80%) as a inseparable mixture of diastereomers (*dr*, 1:1). ^1H NMR (CDCl_3 , 400 MHz): δ 7.85-7.77 (m, 2H), 7.06 (d, $J = 14.38$ Hz, 1H), 6.96-6.89 (m, 2H), 4.63-4.55 (m, 0.44 H), 4.48-4.41 (m, 0.45 H), 3.84 (s, 3H), 2.49-2.25 (m, 2.8H), 2.05-1.9 (m, 0.7H), 1.79-1.71 (0.52 H) 1.43 (d, $J = 6.13$ Hz, 1.5H), 1.33 (d, $J = 6.25$ Hz, 1.5H); ^{13}C NMR (CDCl_3 , 101 MHz): δ 169.5, 160.7, 140.9, 140.8, 133.7, 133.4, 129.0, 121.7, 121.6, 114.1, 112.0, 111.8, 79.7, 78.1, 55.3, 37.3, 35, 32.2, 31.4, 22, 21.2; FTIR (cm^{-1}) 3020, 2926, 2856, 1759, 1008, 1511, 1456, 1378, 1337, 1222, 1178, 1101, 939, 837, 758, 668; HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{17}\text{O}_4$ 261.1121; found 261.1125.

3-(4-Fluorophenyl)-7-methyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2s):

Following *General Procedure F*, to the mixture of ethyl 2-(4-fluorophenyl)-2,7-dihydroxyoct-3-ynoate (**1s**) (0.1 g, 0.34 mmol) in anhydrous CH_2Cl_2 (5 mL) was added $\text{Bi}(\text{OTf})_3$ (0.022 g, 0.034 mmol) under argon atmosphere to obtain 3-(4-fluorophenyl)-7-methyl-1,6-dioxaspiro[4.4]non-3-en-2-one (**2s**) (0.049 g, 74%) as a


inseparable mixture of diastereomers (*dr*, 1:1). ^1H NMR (CDCl_3 , 400 MHz): δ 7.94-7.78 (m, 2H), 7.19-7.04 (m, 3H), 4.67-4.55 (m, 0.42H), 4.51-4.43 (m, 0.41H), 2.60-2.22 (m, 3H), 2.08-1.86 (m, 1H), 1.82-1.72 (m, 0.58H), 1.44 (d, $J = 6.13$ Hz, 1.44H), 1.34 (d, $J = 6.25$ Hz, 1.56H); ^{13}C NMR (CDCl_3 , 101 MHz): δ 169.1, 163.6 ($J = 250.24$ Hz), 142.8 ($J = 11.44$ Hz), 129.5 ($J = 8.39$ Hz), 125.2, 115.8 ($J = 22.12$ Hz), 111.9, 111.8, 79.9, 78.3, 44.0, 42.6, 37.2, 35.0, 32.1, 31.3, 22.0, 21.1; ^{19}F NMR (CDCl_3 , 376 MHz): δ -110.5; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{14}\text{H}_{13}\text{O}_3\text{FNa}$ 271.0741; found 271.0739.

4'-Methyl-3a, 4, 5, 6, 7, 7a-hexahydro-3H, 5'H-spiro [benzofuran-2, 2'-furan]-5'-one (2t):

Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(2-hydroxycyclohexyl)-2-methylpent-3-ynoate (**1t**) (0.05 g, 0.2 mmol) in anhydrous CH₂Cl₂ (0.5 mL) was added Bi(OTf)₃ (0.02 g, 0.02 mmol) under argon atmosphere to


obtain 4'-methyl-3a, 4, 5, 6, 7, 7a-hexahydro-3H, 5'H-spiro [benzofuran-2, 2'-furan]-5'-one (**2t**) as two separable diastereomers (**2t** and **2t'**) in 8:2 ratio (0.023 g, 56% and 0.006 g, 15%) as a solid. TLC: *R_f* = 0.6 (SiO₂, 20% EtOAc/hexanes); relative stereochemistry was assigned based on NOE analysis.

Major diastereomer (**2t**): ¹H NMR (CDCl₃, 400 MHz): δ 6.72(s, 1H), 3.66-3.53 (m, 1H), 2.35 (dd, *J* = 13.4, 7.9 Hz, 1H), 2.2-2.06 (m, 2H), 1.99-1.8 (m, 5H), 1.81-1.74 (m, 1H), 1.62-1.53 (m, 1H), 1.43-1.21 (m, 4H); ¹³C NMR (CDCl₃, 101 MHz): δ 171.9, 145.8, 131.2, 111.8, 84.7, 46.3, 39.8, 30.5, 28.5, 25.5, 24.0, 10.3; FTIR (cm⁻¹) 3017, 2940, 2841, 1759, 1643, 1456, 1216, 1023, 927, 846, 760, 668; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₂H₁₇O₃ 209.1172; found 209.1176.



Minor diastereomer (**2t'**): ¹H NMR (CDCl₃, 500 MHz): δ 6.71(s, 1H), 3.39 (td, *J* = 10.7, 3.8 Hz, 1H), 2.17-2.11 (m, 2H), 2.1-1.94 (m, 1H), 1.93-1.8 (m, 5H), 1.78-1.69 (m, 1H), 1.57-1.42 (m, 1H), 1.4-1.21 (m, 3H), 1.19-1.08 (m, 1H); ¹³C NMR (CDCl₃, 126 MHz): δ 171.3, 145.9, 132.3, 111.4, 86.7, 43.7, 41.5, 31.3, 28.5, 25.5, 24.2, 10.4; FTIR (cm⁻¹) 2926, 2858, 1767, 1662, 1454, 1375, 1312, 1253, 1158, 1113, 1056, 973, 928, 863, 759; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₂H₁₇O₃ 209.1172; found 209.1176.

4'-(4-Nitrophenyl)-3a,4,5,6,7,7a-hexahydro-3H,5'H-spiro[benzofuran-2,2'-furan]-5'-one (2u):



Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-5-(2-hydroxycyclohexyl)-2-(4-nitrophenyl)pent-3-ynoate (**1u**) (0.05 g, 0.14 mmol) in anhydrous CH₂Cl₂ (0.5


mL) was added Bi(OTf)₃ (0.009 g, 0.014 mmol) under argon atmosphere to obtain 4'-methyl-3a, 4, 5, 6, 7, 7a-hexahydro-3H, 5'H-spiro [benzofuran-2, 2'-furan]-5'-one (**2u**) as two separable diastereomers (**2u** and **2u'**) in 7:3 ratio (yield: 0.023 g, 52% and 0.01 g, 23% isolated yield) as a white solid. TLC: *R_f* = 0.6 (SiO₂, 20% EtOAc/hexanes).

Major diastereomer **2u**: ¹H NMR (CDCl₃, 400 MHz): δ 8.32-8.22 (m, 2H), 8.09-7.97 7.38 (s, 1H), 3.69 (td, *J* = 3.75, 10.63 Hz, 1H), 2.50 (dd, *J* = 7.5, 13.63 Hz 1H), 2.28-2.17 (m, 2H), 2.04-1.88 (m, 2H), 1.85-1.76 (m, 1H), 1.74-1.61 (m, 1H), 1.49-1.28 (m, 4H); ¹³C NMR (CDCl₃, 101 MHz): δ 168.6, 148.3, 147.4, 135.0, 130.6, 128.5, 123.9, 111.1, 85.3, 46.5, 40.1, 30.6, 28.5, 25.4, 24.0; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₇H₁₈O₅N 316.1179; found 316.1187.

Minor diastereomer **2u'**: ¹H NMR (CDCl₃, 400 MHz): δ 8.34-8.21 (m, 2H), 8.10-7.98 (m, 2H), 7.42 (s, 1H), 3.55-3.40 (m, 1H), 2.36-2.25 (m, 1H), 2.24-2.15 (m, 1H), 2.11-1.98 (m, 3H), 1.97-1.88 (m, 1H), 1.85-1.76 (m, 1H), 1.62-1.54 (m, 1H), 1.37-1.21 (m, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 168.1, 148.3, 147.9, 135.0, 131.7, 128.4, 123.9, 110.8, 87.3, 43.8, 41.8, 31.3, 28.5, 24.4, 24.2; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₇H₁₈O₅N 316.1179; found 316.1178.


7. Synthesis of [6,5]-unsaturated oxaspirolactones from propargylic diol esters

3-Methyl-1, 6-dioxaspiro [4.5] dec-3-en-2-one (4a):




Following *General Procedure F*, to the mixture of ethyl 2, 8-dihydroxy-2-methyloct-3-ynoate (**3a**) (0.086 g, 0.4 mmol) in an anhydrous CH₂Cl₂ (2 mL) was added Bi(OTf)₃ (0.026 g, 0.04 mmol) under argon atmosphere to obtain 3-methyl-1,6-dioxaspiro[4.5]dec-3-en-2-one(**4a**) (0.0047 g, 70%) as a colourless liquid. TLC: *R_f* = 0.2 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 6.81-6.67(m, 1H), 4.02 (td, *J* = 3.81, 11.4Hz, 1H), 3.95-3.84 (m, 1H), 2-1.93 (m, 1H), 1.91 (s, 3H), 1.87-1.79 (m, 2H), 1.73-1.66 (m, 3H); ¹³C NMR (CDCl₃, 101 MHz): δ 171.9, 147.2, 131.9, 104.8, 65.0, 32.3, 24.1, 19.1, 10.5; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₉H₁₃O₃ 169.1459; found 169.0869.

3-Phenyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (4b):



Following *General Procedure F*, to the mixture of ethyl 2,8-dihydroxy-2-phenyloct-3-ynoate (**3b**) (0.1 g, 0.36 mmol) in anhydrous CH₂Cl₂ (5 mL) was add Bi(OTf)₃ (0.024 g, 0.036 mmol) under argon atmosphere to obtain 3-phenyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4b**) (0.063 g, 75%). TLC: *R_f* = 0.40 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 7.90-7.77 (m, 2H), 7.47-7.35(m, 3H), 7.22 (s, 1H), 4.09 (td, *J* = 3.05, 11.44 Hz, 1H), 4.0-3.90 (m, 1H), 2.05-1.69 (m, 6H); ¹³C NMR (CDCl₃, 126 MHz): δ 169.6, 145.6, 133.2, 129.7, 129.1, 128.7, 127.5, 104.0, 65.0, 32.5, 24.1, 19.1; FTIR (cm⁻¹) 3074, 3022, 2946, 1760, 1645, 1484, 1448, 1367, 1305, 1261, 1222, 1112, 1051, 1006, 947, 927, 850, 754, 691; HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₄H₁₅O₃ 231.1016; found 231.1019.


3-(4-Methoxyphenyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (4c):



Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-2-(4-methoxyphenyl)-8-((tetrahydro-2*H*-pyran-2-yl)oxy)oct-3-ynoate (**5d**) (0.2 g, 0.652 mmol) in anhydrous CH₂Cl₂ (5 mL) was add Bi(OTf)₃

(0.043 g, 0.0652 mmol) under argon atmosphere to obtain 3-(4-methoxyphenyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4c**) (0.118 g, 70%). TLC: R_f = 0.40 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.81 (d, J = 9.16 Hz, 2H), 7.11 (s, 1H), 6.93 (d, J = 9.16 Hz, 2H), 4.08 (td, J = 3.21, 11.45 Hz, 1H), 3.97-3.91(m, 1H), 3.84 (s, 3H), 2.05-1.73 (m, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 169.9, 160.7, 143.3, 132.5, 128.9, 121.6, 114.1, 103.9, 65.0, 55.3, 32.6, 24.2, 19.2; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₅H₁₇O₄ 261.1121; found 261.1125.


3-(*p*-Tolyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one(**4d**):



Following *General Procedure F*, to the mixture of ethyl 2,8-dihydroxy-2-(*p*-tolyl)oct-3-ynoate (**3d**) (0.1 g, 0.34 mmol) in anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.023 g, 0.034 mmol) under argon atmosphere to obtain 3-(*p*-tolyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4d**) (0.068 g, 81%).

TLC: R_f = 0.40 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.74-7.68, (m, 2H), 7.22-7.17(m, 2H), 7.15(s, 1H), 4.06 (td, J = 3.81, 11.44 Hz, 1H), 3.96-3.89 (m, 1H), 2.35 (s, 3H), 2.05-1.62 (m, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 169.7, 144.6, 139.8, 132.8, 129.3, 127.3, 126.1, 103.9, 64.9, 32.4, 24.1, 21.3, 19.1; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₅H₁₇O₃ 245.1172; found 245.1170.

3-(4-Fluorophenyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4e**):




Following *General Procedure F*, to the mixture of ethyl 2-(4-fluorophenyl)-2,8-dihydroxyoct-3-ynoate (**3e**) (0.1 g, 0.34 mmol) in anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.02 g, 0.034 mmol) under argon atmosphere to obtain 3-(4-fluorophenyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4e**) (0.058 g, 69%).

TLC: R_f = 0.40 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 7.93-7.74 (m, 2H), 7.18 (s, 1H), 7.14-7.05 (m, 2H), 4.08 (td, J = 3.66, 11.45 Hz, 1H), 4.01-3.88 (m, 1H), 2.09-1.71 (m, 6H); ¹³C NMR (CDCl₃, 101 MHz): δ 169.5, 163.7 (J = 250.24 Hz), 145.1 (J = 2.29 Hz), 132.1, 129.5 (J = 8.39 Hz), 125.2, 115.8 (J = 21.36 Hz), 104.0, 65.0,


32.4, 24.1, 19.1; ^{19}F NMR (CDCl_3 , 376 MHz): δ -110.5; HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{14}\text{O}_3\text{F}$ 249.0921; found 249.0919.

3-(Phenylethynyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4f**):




Following *General Procedure F*, to the mixture of ethyl 2,8-dihydroxy-2-(phenylethynyl)oct-3-ynoate (**3f**) (0.1 g, 0.33 mmol) in anhydrous CH_2Cl_2 (5 mL) was added $\text{Bi}(\text{OTf})_3$ (0.021 g, 0.033 mmol) under argon atmosphere to obtain 3-(phenylethynyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4f**) (0.064 g, 76%). TLC: R_f = 0.40 (SiO_2 , 20% EtOAc/hexanes); ^1H NMR (CDCl_3 , 400 MHz): δ 7.59-7.50 (m, 2H), 7.41-7.33 (m, 3H), 7.16 (s, 1H), 4.29 (td, J = 3.81, 8.39 Hz, 1H), 4.16-4.08 (m, 1H), 2.39-2.14 (m, 6H); ^{13}C NMR (CDCl_3 , 101 MHz): δ 167.2, 149.6, 132.1, 129.6, 128.4, 121.5, 120.8, 113.3, 97.9, 78.1, 70.8, 35.8, 31.9, 24.2, 22.7, 14.1; HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{15}\text{O}_3$ 255.1016; found 255.1006.


3-(Naphthalene-2-yl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4g**):



Following *General Procedure F*, to the mixture of ethyl 2,8-dihydroxy-2-(naphthalene-2-yl)oct-3-ynoate (**3g**) (0.1 g, 0.31 mmol) in anhydrous CH_2Cl_2 (5 mL) was added $\text{Bi}(\text{OTf})_3$ (0.02 g, 0.031 mmol) under argon atmosphere to obtain 3-phenyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4g**) (0.071 g, 83%). TLC: R_f = 0.6 (SiO_2 , 20% EtOAc/hexanes); ^1H NMR (CDCl_3 , 400 MHz): δ 7.89-7.81 (m, 3H), 7.58-7.51 (m, 1H), 7.5-7.37 (m, 3H), 7.2 (s, 1H), 4.17-4.02 (m, 1H), 4.01-3.87 (m, 1H), 2.06-1.66 (m, 6H); ^{13}C NMR (CDCl_3 , 101 MHz): δ 170.2, 150.4, 133.6, 133.5, 131.1, 129.8, 128.6, 127.7, 126.7, 126.6, 126.1, 125.1, 124.4, 104.8, 65.1, 32.6, 24.1, 19.1; FTIR (cm^{-1}) 3019, 2944, 1764, 1650, 1592, 1508, 1448, 1367, 1298, 1225, 1130, 1051, 998, 921, 862, 760, 664; HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{O}_3$ 281.1172; found 281.1178.

3-(1-Methyl-1*H*-indol-3-yl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (4k):


Following *General Procedure F*, to the mixture of ethyl 2-hydroxy-2-(1-methyl-1*H*-indol-3-yl)-8-((tetrahydro-2*H*-pyran-2-yl)oxy)oct-3-ynoate (**3k**) (0.1 g, 0.24 mmol) in anhydrous EtOH (5 mL) was added PTSA (0.046 g, 0.024 mmol) under argon atmosphere to obtain 3-(1-methyl-1*H*-indol-3-yl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4k**) (0.051 g, 75%). TLC: R_f = 0.40 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 8.17 (s, 1H), 7.8 (d, J = 8.1 Hz, 1H), 7.4 (d, J = 8.37 Hz, 1H), 7.36-7.31 (m, 1H), 7.3-7.24 (m, 1H), 7.2 (s, 1H), 4.18-4.08 (m, 1H), 4.03-3.96 (m, 1H), 3.86 (s, 3H), 2.1-1.98 (m, 2H), 1.94-1.85 (m, 2H), 1.82-1.69 (m, 2H); ¹³C NMR (CDCl₃, 126 MHz): δ 171.2, 137.8, 131.6, 126.3, 122.6, 120.8, 119.8, 110.0, 105.4, 65.1, 33.2, 33.02, 24.3, 19.4; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₇H₁₈O₃N 284.1281; found 284.1281.

3,7-Dimethyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (4h):

Following *General Procedure F*, to the mixture of ethyl 2,8-dihydroxy-2-methyloct-3-ynoate (**3h**) (0.1 g, 0.44 mmol) in anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.029 g, 0.044 mmol) under argon atmosphere to obtain 3,7-dimethyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4h**) (0.07 g, 88%) as a colourless liquid. TLC: R_f = 0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 6.76 (q, J = 1.63 Hz, 1H), 4.15-4.06 (m, 1H), 2.09-1.94 (m, 1H), 1.92 (d, J = 1.63 Hz, 3H), 1.85-1.78 (m, 1H), 1.77-1.68 (m, 3H), 1.22 (d, J = 6.13 Hz, 1H), 1.19 (d, J = 6.25 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 172.1, 147.5, 131.9, 105.4, 70.9, 31.8, 31.6, 29.7, 25.4, 21.7, 19.4, 10.5; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₀H₁₅O₃ 183.1016; found 183.1015.

7-Methyl-3-phenyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (4i):


Following *General Procedure F*, to the mixture of ethyl 2,8-dihydroxy-2-phenylnon-3-ynoate (**3i**) (0.1 g, 0.34 mmol) in anhydrous CH₂Cl₂ (5 mL) was added Bi(OTf)₃ (0.023 g, 0.034 mmol) under argon atmosphere to obtain 3-phenyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4i**) (0.071 g,



84%) as a colourless liquid. TLC: R_f = 0.6 (SiO₂, 20% EtOAc/hexanes); relative stereochemistry was assigned based on NOE analysis. ¹H NMR (CDCl₃, 500 MHz): δ 7.89 - 7.81 (m, 2H), 7.44 - 7.38 (m, 3H), 7.23 (s, 1H), 4.21 - 4.13 (m, 1H), 2.08 - 1.99 (m, 1H), 1.90 - 1.82 (m, 2H), 1.80 - 1.74 (m, 2H), 1.42 - 1.33 (m, 1H), 1.22 (d, J = 6.49 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 169.6, 145.8, 132.9, 129.6, 129.1, 128.6,

127.4, 104.5, 70.9, 32.0, 31.5, 21.7, 19.4; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₅H₁₇O₃ 245.1172; found 275.1174.


7-Butyl-3-methyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4l**):



Following *General Procedure F*, to the mixture of ethyl 8-((*tert*-butyldimethylsilyl)oxy)-2-hydroxy-2-methyldodec-3-ynoate. (**5b**) (0.1 g, 0.26 mmol) in anhydrous CH₂Cl₂ (5 mL) was add Bi(OTf)₃ (0.0 g, 0.026 mmol) under argon atmosphere to obtain 3-phenyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4l**) (0.045 g, 78%). TLC: R_f =

0.6 (SiO₂, 20% EtOAc/hexanes); ¹H NMR (CDCl₃, 500 MHz): δ 6.75 (q, J = 1.63 Hz, 1H), 3.99-3.87 (m, 1H), 2.01-1.92 (m, 1H), 1.91 (d, J = 1.63 Hz, 3H), 1.85-1.67 (m, 4H), 1.41-1.18 (m, 7H), 0.91-0.85 (m, 3H); ¹³C NMR (CDCl₃, 126 MHz): δ 172.2, 147.6, 131.7, 105.5, 74.7, 35.7, 32.2, 29.7, 27.3, 22.7, 19.5, 14.0, 10.5; HRMS (ESI) m/z : [M+Na]⁺ calcd for C₁₃H₂₀O₃Na 247.1305; found 247.1304.

3,7,7-Trimethyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4j**):





Following *General Procedure F*, to the mixture of ethyl 2,8-dihydroxy-2,8-dimethylnon-3-ynoate (**3j**) (0.1 g, 0.41mmol) in anhydrous CH₂Cl₂ (5 mL) was add Bi(OTf)₃ (0.027 g, 0.041 mmol) under argon atmosphere to obtain 3-phenyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (**4j**) (0.04 g, 50%); ¹H



NMR (CDCl₃, 500 MHz): δ 6.72-6.69 (m, 1H), 1.90 (s, 3H), 1.72-1.68 (m, 3H), 1.39-1.38 (m,



3H), 1.25 (m, 6H); ^{13}C NMR (CDCl_3 , 126 MHz): δ 172.2, 148.3, 131.7, 105.6, 75.4, 35.1, 32.1, 31.8, 26.4, 16.1, 10.5; HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{16}\text{O}_3$ 197.1172; found 197.1172.



8.

^1H , ^{13}C and 2D-NMR Spectra



Ethyl 2-hydroxy-2-methyl-5-(1-(((tetrahydro-2H-pyran-2-yl) oxy) methyl) cyclohexyl) pent-3-ynoate (S22):

Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclohexyl)-2-methylpent-3-ynoate (1a):



Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclohexyl)-2-phenylpent-3-ynoate (1b):



Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclohexyl)-2-(4-methoxyphenyl)pent-3-ynoate (1c):



Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclohexyl)-2-(*p*-tolyl)pent-3-ynoate (1d):





Ethyl 5-(1-(((*tert*-butyldimethylsilyl)oxy)methyl)cyclohexyl)-2-hydroxy-2-(phenylethynyl)pent-3-ynoate (S24):







Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclohexyl)-2-(phenylethynyl)pent-3-ynoate (1e):



Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-methylpent-3-ynoate (1f):



Ethyl 5-(1-(((*tert*-butyldimethylsilyl)oxy)methyl)cyclopentyl)-2-hydroxy-2-phenylpent-3-ynoate (5a):






Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-phenylpent-3-ynoate (1g):



Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-(4-nitrophenyl)pent-3-ynoate(1h):



Ethyl 5-(1-(((*tert*-butyldimethylsilyl)oxy)methyl)cyclopentyl)-2-oxopent-3-ynoate (S27):



Ethyl 2-hydroxy-5-(1-(hydroxymethyl)cyclopentyl)-2-(1*H*-indol-3-yl)pent-3-ynoate (1i):



Ethyl 2,7-dihydroxy-2,6,6-trimethylhept-3-ynoate (1j):


Ethyl 2,7-dihydroxy-6,6-dimethyl-2-phenylhept-3-ynoate (1k):

Ethyl 2,7-dihydroxy-2-(4-methoxyphenyl)-6,6-dimethylhept-3-ynoate (11):



Ethyl 2,7-dihydroxy-6,6-dimethyl-2-(*p*-tolyl)hept-3-ynoate (1m):

Ethyl 2-(4-fluorophenyl)-2,7-dihydroxy-6,6-dimethylhept-3-ynoate (1n):


Ethyl 2,7-dihydroxy-2-methylhept-3-ynoate (1o):



Ethyl 2-hydroxy-2-phenyl-7-((tetrahydro-2H-pyran-2-yl)oxy)hept-3-ynoate (5e):

^1H NMR, 400 MHz
 CDCl_3





^{13}C NMR, 101 MHz
 CDCl_3




Ethyl 2,7-dihydroxy-2-phenylhept-3-ynoate(**1p**):



Ethyl 2-hydroxy-7-((4-methoxybenzyl)oxy)-2-methylhept-3-ynoate (5f):




Ethyl 2,7-dihydroxy-2-(*p*-tolyl)hept-3-ynoate (1q):


Ethyl 7-((*tert*-butyldimethylsilyl)oxy)-2-hydroxy-2-(4-methoxyphenyl)oct-3-ynoate (S33):



¹H NMR, 400 MHz
CDCl₃







¹³C NMR, 101 MHz
CDCl₃







Ethyl 2,7-dihydroxy-2-(4-methoxyphenyl)oct-3-ynoate (**1r**):



Ethyl 7-((*tert*-butyldimethylsilyl)oxy)-2-(4-fluorophenyl)-2-hydroxyoct-3-ynoate (S34):

Ethyl 2-(4-fluorophenyl)-2,7-dihydroxyoct-3-ynoate(1s):


Ethyl 2-hydroxy-5-(2-hydroxycyclohexyl)-2-methylpent-3-ynoate (1t):


Ethyl 2-hydroxy-5-(2-hydroxycyclohexyl)-2-(4-nitrophenyl) pent-3-ynoate (1u):


Ethyl 2, 8-dihydroxy-2-methyloct-3-ynoate (3a):



Ethyl 2-hydroxy-2-phenyl-8-((tetrahydro-2H-pyran-2-yl) oxy) oct-3-ynoate (S36):



Ethyl 2,8-dihydroxy-2-phenyloct-3-ynoate (3b):








Ethyl 2-hydroxy-2-(4-methoxyphenyl)-8-((tetrahydro-2H-pyran-2-yl)oxy)oct-3-ynoate (5d):



Ethyl 2,8-dihydroxy-2-(4-methoxyphenyl)oct-3-ynoate (3c):


Ethyl 2-hydroxy-8-((tetrahydro-2H-pyran-2-yl)oxy)-2-(*p*-tolyl)oct-3-ynoate (S37):



Ethyl 2,8-dihydroxy-2-(*p*-tolyl)oct-3-ynoate (**3d**):



Ethyl 2-(4-fluorophenyl)-2-hydroxy-8-((tetrahydro-2H-pyran-2-yl)oxy)oct-3-ynoate (S38):





Ethyl 8-((*tert*-butyldimethylsilyl)oxy)-2-hydroxy-2-(phenylethynyl)oct-3-ynoate (S40):



Ethyl 2,8-dihydroxy-2-(phenylethynyl)oct-3-ynoate (3f):



Ethyl 2-hydroxy-2-(naphthalen-2-yl)-8-((tetrahydro-2H-pyran-2-yl) oxy) oct-3-ynoate (S41):



Ethyl 2, 8-dihydroxy-2-(naphthalen-2-yl) oct-3-ynoate (3g):



Ethyl 2-hydroxy-2-(1-methyl-1*H*-indol-3-yl)-8-((tetrahydro-2*H*-pyran-2-yl)oxy)oct-3-ynoate (3k):







Ethyl 2,8-dihydroxy-2-methylnon-3-ynoate (3h):



Ethyl 2,8-dihydroxy-2-phenylnon-3-ynoate (**3i**):



Ethyl 8-((*tert*-butyldimethylsilyl)oxy)-2-hydroxy-2-methyldodec-3-ynoate (**5b**):



Triethyl((2-methylhept-6-yn-2-yl)oxy)silane (S43):



Ethyl 2-hydroxy-2,8-dimethyl-8-((triethylsilyl)oxy)non-3-ynoate (**5c**):



Ethyl 2,8-dihydroxy-2,8-dimethylnon-3-ynoate (3j):



3-Methyl-1,14-dioxadispiro[4.1.5^{7.2}5]tetradec-3-en-2-one (2a):



3-Phenyl-1, 14-dioxadispiro [4.4.5^{7.25}] tetradec-3-en-one (2b):



3-(4-Methoxyphenyl)-1,14-dioxadispiro[4.1.5⁷.2⁵]tetradec-3-en-2-one (2c):



3-(*p*-Tolyl)-1,14-dioxadispiro[4.1.5^{7.2}5]tetradec-3-en-2-one (2d):


3-(Phenylethynyl)-1,14-dioxadispiro[4.1.5⁷.2⁵]tetradec-3-en-2-one (2e):

3-Methyl-1,13-dioxadispiro[4.1.4^{7.25}]tridec-3-en-2-one (2f):



3-Phenyl-1,13-dioxadispiro[4.1.4⁷.2⁵]tridec-3-en-2-one (2g) :

3-(4-Nitrophenyl)-1,13-dioxadispiro[4.1.4^{7.2}5]tridec-3-en-2-one (2h):


3-(1*H*-indol-3-yl)-1,13-dioxadispiro[4.1.4^{7.2}5]tridec-3-en-2-one (2i):


3,8,8-Trimethyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2j):



^1H NMR 400 MHz
 CDCl_3






^{13}C NMR 101 MHz
 CDCl_3




8,8-Dimethyl-3-phenyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2k):


3-(4-Methoxyphenyl)-8,8-dimethyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2l):


8,8-Dimethyl-3-(*p*-tolyl)-1,6-dioxaspiro[4.4]non-3-en-2-one (2m):



3-(4-Fluorophenyl)-8,8-dimethyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2n):







^{19}F NMR, 376 MHz
 CDCl_3







3-Methyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2o):



3-Methyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2o):


3-Methyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2o):



3-Phenyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2p):



3-(*p*-Tolyl)-1,6-dioxaspiro[4.4]non-3-en-2-one (2q):

3-(4-Methoxyphenyl)-7-methyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2r):



3-(4-Fluorophenyl)-7-methyl-1,6-dioxaspiro[4.4]non-3-en-2-one (2s):





Methyl-3a,4,5,6,7,7a-hexahydro-3H,5'H-spiro[benzofuran-2,2'-furan]-5'-one (2t):





COSY: (2t)





NOESY: (2t)





HMBC: (2t)




4'-(4-Nitrophenyl)-3a,4,5,6,7,7a-hexahydro-3H,5'H-spiro[benzofuran-2,2'-furan]-5'-one (2u):





4'-(4-Nitrophenyl)-3a,4,5,6,7,7a-hexahydro-3*H*,5'*H*-spiro[benzofuran-2,2'-furan]-5'-one (2u')


3-Methyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (4a):



3-Phenyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (4b):



^1H NMR 500 MHz
 CDCl_3






^{13}C NMR, 126 MHz
 CDCl_3







3-(4-Methoxyphenyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (4c):



3-(*p*-Tolyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (4d):



3-(4-Fluorophenyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (4e):



3-(Phenylethynyl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (4f):



3-(Naphthalen-2-yl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (4g):

3-(1-Methyl-1*H*-indol-3-yl)-1,6-dioxaspiro[4.5]dec-3-en-2-one (4k):



3,7-Dimethyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (4h):

2D NMR analysis of 4h:



COSY: (4h)




NOESY: (4h)




HSQC: (4h)





7-Methyl-3-phenyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (4i):



COSY: (4i)



NOESY: (4i)



HSQC: (4i)



7-Butyl-3-methyl-1,6-dioxaspiro[4.5]dec-3-en-2-one (4l):